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Etoposide is a widely used topoisomerase II inhibitor particularly useful in the clinic for 
treatment of disseminated tumors, including childhood leukemia. However, its use is associated 
with the increased risk of development of secondary acute myelogenous leukemias. The 
mechanism behind this is still unclear. It was hypothesized that etoposide ortho-quinone, a 
reactive metabolite previously shown to be generated in vitro by myeloperoxidase, the major 
oxidative enzyme in the bone marrow cells from which the secondary leukemias arise, might be 
a contributor to the development of treatment-related secondary leukemias. Experiments showed 
that the glutathione adduct of etoposide ortho-quinone was formed in myeloperoxidase-
expressing human myeloid leukemia HL60 cells treated with etoposide, that its formation was 
enhanced by addition of the myeloperoxidase substrate hydrogen peroxide, and that the 
glutathione adduct level was dependent on myeloperoxidase. Both the normoisotopic and a 
stable isotope-labeled version of the glutathione adduct were synthesized. The latter was used for 
liquid chromatography-mass spectrometry-based quantitative analyses of the adduct formed by 
the cells.  
Discodermolide and dictyostatin are two strucuturally related natural products that 
possess potent microtubule stabilizing activity. Discodermolide advanced to Phase II clinical 
trials, but the trials were halted for unannounced reasons. Here, both agents were found to be 
extensively metabolized by human liver microsomes in vitro. In order to determine the metabolic 
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soft spots in the molecules, the chemical structures of the metabolites of discodermolide and 
dictyostatin were elucidated by liquid chromatography-mass spectrometry. At least eight 
metabolites of discodermolide and six metabolites of dictyostatin were formed in human liver 
microsomes in vitro. The terminal diene groups on discodermolide and dictyostatin were found 
to be the metabolic soft spots. Results from these studies can be used in future medicinal 
chemistry design and synthesis work to decrease metabolic rate and improve drug metabolism 
and pharmacokinetic properties, therefore decreasing the doses needed and perhaps even the 
toxicity. 
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1.0  INTRODUCTION 
1.1 OVERVIEW 
An understanding of the metabolism of chemicals is important in the drug discovery and 
development processes. Most compounds that have failed in development or after being 
approved have done so because of undesirable side effects or toxicities (so-called adverse drug 
reactions). These toxicities may be observed in a short period of time after administration, or 
sometimes they are only detected after long term use. In most cases, biotransformation of parent 
compounds often contributes to idiosyncratic adverse drug reactions. Toxicities induced by 
biotransformation can be caused by metabolites themselves, or by reactive metabolites formed. 
The biotransformation leading to reactive metabolites is known as “bioactivation”. There are 
several mechanisms of bioactivation-induced adverse drug reactions, and some functional groups 
are particularly susceptible to bioactivation.  Another reason that a compound fails in clinical 
trials is poor pharmacokinetic properties. Recently, a trend in the drug discovery process is to 
elucidate the chemical structures of metabolites of the parent compound in an early stage so as to 
determine the metabolic “soft spots” (the sites on the chemical structure which can be attacked 
by metabolic enzymes) in the compound. Characterization of metabolites formed in vitro or in 
vivo has therefore become more and more crucial in the drug development stage and even in the 
early drug discovery stage. There are several approaches for metabolite structure elucidation, 
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including liquid chromatogram-masspectrometry (LC-MS/MS) and liquid chromatogram-nulcear 
magnetic resonance(LC-NMR). LC-MS/MS is the most common technique applied in metabolite 
identification.  
Etoposide is an approved anticancer drug, discodermolide is an investigational new 
anticancer drug that progressed to Phase II trials, and dictyostatin is a lead agent that could 
perhaps displace/replace discodermolide. Etoposide is a topoisomerase II inhibitor that has been 
widely used for decades. However, the use of etoposide, often in children with cancer, is 
associated with an increased risk of the development of secondary leukemias. The mechanism 
behind this adverse drug reaction is still unknown, but it is suspected to include local metabolism 
by cells that give rise to the secondary leukemias. Discodermolide and dictyostatin are two 
microtubule stabilizing agents derived from different marine sponges. Their metabolism has not 
been studied. It is important to find out the metabolic soft spots of discodermolide and 
dictyostatin to perhaps provide means for improving their pharmacokinetic and toxicological 
properties. The metabolism of these three agents is the subject of this dissertation. 
1.2 BIOACTIVATION AND ADVERSE DRUG REACTIONS 
Adverse drug reactions are a major problem in drug development and a common cause of 
drug recalls and labeling changes. Over 10% of the drugs approved by FDA from 1975 to 2000 
had to be withdrawn from the US market or be fitted with new warning(s) in their labels (Lasser 
KE, et al., 2002). One of the reasons that certain adverse drug reactions are not recognized 
before drug approval is the small numbers of patients enrolled in clinical trials that is not 
sufficient to reveal these negative effects (Uetrecht JP, 2000). The other reason might be the 
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variability among patients in gender, genetic background, underlying disease, and co-
administrated drugs (Kaplowitz N, 2004). Adverse drug reactions are categorized into several 
types. The most common type of adverse drug reactions are predictable reactions, sometimes 
referred to as type A reactions, and most adverse drugs reactions (76-95%) belong to this 
category (Davies DM, 1985).  These adverse drug reactions are usually identified based on the 
pharmacology of the drug in preclinical toxicological evaluations. If toxicity is observed in 
animals at the concentration with anticipated clinical efficacy, the further development of the 
drugs will be stopped. However, some adverse drug reactions do not involve the known 
pharmacological properties of drugs and the dose-response relationship is not well defined. 
These adverse drug reactions are termed idiosyncratic adverse drug reactions. The prediction of 
idiosyncratic adverse drug reactions is impossible at present not only because the incidence rate 
is extremely low, but also because such events typically emerge only after weeks or months of 
therapy; sometimes they are observed only several years after therapy (Uetrecht JP, 2000). Based 
on the reasons above, idiosyncratic adverse drug reactions are usually observed only after the 
drugs are approved and widely used. Idiosyncratic adverse drug reactions are a major reason for 
drug withdrawal in drug development and after the launch into the market. Some drugs induce 
idiosyncratic adverse drug reactions prior to metabolism, but most of them are caused by reactive 
metabolites (Uetrecht JP, 2000). A lot of evidence has been accumulated to show that inadequate 
detoxification of reactive metabolites is the major cause of tissue necrosis, carcinogenicity and 
immune toxicity. In order to decrease idiosyncratic adverse drug reactions, it is imperative that 
the fundamental mechanisms behind these reactions with reactive metabolites are well 
understood.  
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1.2.1 The mechanism of bioactivation-induced adverse drug reactions 
Clinical and experimental evidence shows that idiosyncratic adverse drug reactions are 
mediated by immunological responses, in some cases, or are at least recognized by the immune 
system. For example, idiosyncratic liver injury caused by drugs are often accompanied by some 
clinical symptoms of immune response (Banks et al., 1995); Antibodies against reactive 
metabolite-modified proteins have been found in serum, and the presence of antibodies is 
associated with liver injury (Bougie et al., 1997). Dramatic responses to such agents have been 
reported (Greaves et al., 2001). It is well known that low molecular weight compounds can not 
trigger the immune response unless they covalently bind to or chemically alter proteins or other 
biomacromolecules. Most idiosyncratic adverse drug reactions are caused by reactive 
metabolites of drugs rather than by the drugs themselves. However, the presence of circulating 
antibodies alone is merely a marker for the immune response. In fact, experimental data suggests 
that the liver injury seen in these cases is actually caused by cytotoxic T cells. Most drugs that 
cause idiosyncratic adverse drug effects can be converted to reactive metabolites. On the other 
hand, it is not true that drugs that are converted to reactive metabolites to some degree are always 
associated with an unacceptable risk of idiosyncratic adverse drug reactions. The risk of 
idiosyncratic adverse drug reactions is also influenced by two other factors: one is the amount of 
reactive metabolite(s) that actually binds to macromolecules; the other is the specificity of 
macromolecules bound by reactive metabolites. Meanwhile, the dose of the drug administered 
can also influence the observation of idiosyncratic adverse reactions. If the dose used is low 
enough, the probability that it will cause adverse reactions is also low, even though the drug can 
be efficiently converted to reactive metabolite(s).  
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There may be other risk factors, in addition to covalent binding, that induce adverse 
reactions. This is because the normal reaction to the foreign proteins, the category in which 
covalently modified proteins should be placed, is tolerance. The modified protein alone is 
generally not sufficient to cause idiosyncratic adverse drug reactions (Bonierbale E et al., 1999). 
Meanwhile, if the covalent binding were the only cause of idiosyncratic adverse drug reactions, it 
appears that the binding of reactive metabolites only to the enzyme that formed them is unlikely 
to be associated with adverse reactions. One good example is tienilic acid. Tienilic acid can 
cause idiosyncratic liver toxicity, however it is known to only bind to CYP450 (Bonierbale E et 
al., 1999). These observations imply that other factors might contribute to idiosyncratic adverse 
drug reactions. More recent concepts have invoked the necessity of a “danger signal”. There 
might be some factors that act as danger signals, including cellular stress, cell damage, etc. For 
example, a reactive metabolite can cause upregulation of costimulatory signals on T cells 
(Uetrecht JP, 1999; Pirmohamed et al., 2002).  
Understanding the mechanisms underlying idiosyncratic adverse drug reactions is 
important. Such an understanding can provide a basis to identify susceptible populations, identify 
biomarkers associated with increased risk and assist in lead selection. Although in the past 
several decades, major progress has been made in understanding of idiosyncratic adverse drug 
reactions at the molecular level, the underlying mechanisms are still not clear. There are several 
possible reasons why the mechanisms are still unclear, including the difference between human 
and experimental animal immune systems in many aspects, the availability of animal disease 
models for studying immune response, and the general artificial state of experimental systems 
used in drug studies. 
 5 
1.2.2 Bioactivation pathways of organic functional groups 
Macromolecules, including proteins and DNA, in living tissues are essential components 
for life-sustaining process. In order to maintain the functions of proteins and DNA, their 
structure and sequence should remain intact. If these two fundamental elements of biochemical 
process are disrupted, for example by irreversible covalent binding of reactive metabolites, can 
manifest into cellular damage in some cases, or trigger an immune response. In attempts to 
identify potential idiosyncratic adverse drug reactions, promising drug candidates are generally 
evaluated for toxicity in animal models prior to administration to humans. However, not all 
toxicity caused by reactive metabolites can be identified in preclinical studies due to the limited 
numbers of animal disease models as well as the metabolic differences between animals and 
humans. Furthermore, the number of animals used in preclinical studies is far too low to reveal 
the typical incidence frequency of idiosyncratic adverse drug reactions seen in humans. In order 
to minimize reactive metabolite-mediated safety issues, the formation of reactive metabolites 
should be reduced. Several common functional groups that have the potential to form reactive 
metabolites are described below. 
Aromatic Amines. The bioactivation of aromatic amines is initiated by the formation of 
the N-hydroxylamine intermediate as shown in Figure 1.1. The reactive N-hydroxylamine 
metabolites can undergo conjugation to generate N-O-acetyl conjugates, thereby forming an 
excellent leaving group (acetate). Under the right conditions, this can lead to a highly reactive 
nitrenium ion, which may be the ultimate reactive intermediate involved in DNA adduct and 
covalent protein binding. The reactive N-hydroxylamine can also undergo two-electron oxidation 
to generate the more reactive nitroso intermediate resulting in DNA and protein binding. A 
noteworthy example is procainamide, an aromatic amine. The utility of procainamide has been 
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hampered by its adverse drug reactions. N-Hydroxyprocainamide and nitrosoprocainamide have 
been observed to result from incubation with mouse liver microsomes in vitro, as well as in vivo 
(Freeman RW, et al., 1981). The covalent binding of reactive metabolites of procainamide can be 
prevented by the addition of reducing agents to reduce them to aromatic amines. 
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N
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R
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Protein Modification
 
Figure 1.1 Bioactivation of aromatic amine. 
Aromatic nitro compounds. Aromatic nitro drugs are similar to aromatic amines in that 
they can also be converted to hydroxylamine and nitroso intermediate metabolites. The 
formation of nitroso intermediate metabolite is initiated by the reduction of the nitro group 
(Figure 1.2), often by nitroreductases in gut bacteria. A well-known example of a drug that  
causes idiosyncratic adverse drug reactions is talcapone. Talcapone is a drug that was approved 
for the treatment of Parkinson’s disease. It was withdrawn from the market because of a high 
incidence of liver toxicity (Watkins P, 2000). The nitro group in talcapone was shown to in fact 
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be reduced to the nitroso and hydroxylamine intermediates, reactive metabolites that are 
presumed to be responsible for the  idiosyncratic adverse drug reactions (Jorga K, et al., 1999). 
R
NO2
R
N
O
R
N
H OH
Protein Modification  
Figure 1.2 Bioactivation of aromatic nitro compounds. 
Hydrazine containing drugs. Hydrazine-based drugs have the potential to cause 
idiosyncratic adverse drug reactions. For instance, isoniazid is associated with a relatively high 
incidence of severe hepatotoxicity and this is well stated on its warning label. The mechanism of 
hydrazine drug-induced idiosyncratic adverse drug reactions is thought to be related to the 
bioactivation of hydrazines. Hydrazines appear to be oxidized by peroxidases to diazines and 
diazonium ions, two reactive intermediates. Diazonium ions can further lose nitrogen to form 
very reactive radicals or carbocations. These very reactive species can then covalently modify 
macromolecules. 
HN
R
NH2
N
R
NH
R·
N2
Protein Binding
 
Figure 1.3 Bioactivation of hydrazine. 
Quinone-imine reactive metabolites. Quinone-imines are reactive electrophiles that 
readily form conjugates with proteins and endogenous glutathione (GSH) through Michael 
reactions. Such a metabolite is likely responsible for the idiosyncratic adverse drug reactions 
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associated with some drugs (Clarke JB, et al., 1991), particularly the liver toxicity caused by 
high doses of acetaminophen. Quinone-imine formation occurs during normal biological 
oxidation of parent compounds. 
OH
NH2
O
NH
Protein Modification 
or GSH adduct
 
Figure 1.4 Bioactivation of 1,4-aminophenol. 
Quinones. Quinones are Michael acceptors and can covalently react with cellular 
electrophiles such as proteins and DNA, resulting in cell damage and an immune response. They 
can not only cause macromolecule modification by direct reaction, but also initiate redox cycles 
through their hydroquinone and semiquinone forms, finally leading to the formation of reactive 
oxygen species. Quinones are typically generated from aromatic compounds through oxidation. 
OH
OH
O
O
Protein modification
or GSH adduct
 
Figure 1.5 Bioactivation of 1,4-hydroquinone. 
Furans. Furan is an environmental contaminant in smog, tobacco smoke and canned 
foods. Furan is a known hepatic and renal toxicant. It is also a potential human carcinogen 
(Sirica AE, 1996). Bioactivation of furan moiety is believed to be a major cause of idiosyncratic 
adverse drug reactions in molecules that contain them. Furan is first converted to an epoxide, 
which can be converted to toxic butene-1,4-dial (Chen LJ, et al., 2006). The hepatocarcinogen 
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aflatoxin B1 is activated to its ultimate carcinogenic form by this mechanism (Guengerich FP, et 
al., 1998). 
O O
O
O O
DNA or protein adduct
 
Figure 1.6 Bioactivation of furan. 
 
1.2.3 Enzymes responsible for the formation of reactive metabolites  
The cytochrome P450 system is the essential group of enzymes associated with reactive 
metabolite formation. It is also the dominant system of enzymes in the liver, which is the major 
organ of drug bioactivation (Rooney PH, et al., 2004). Cytochromes P450 are responsible for the 
oxidation of a wide range of drug substrates, and comprise the major route of what is termed 
Phase I metabolism. Phase I metabolism is conversion of endo- and xenobiotics to more polar 
compounds through an oxidation that generally leads to addition of an oxygen atom to the 
xenobiotic. However, the liver is not the only target organ in which idiosyncratic adverse drug 
reactions take place; other organs and tissues, such as intestine, kidney, skin, lung, etc., contain 
different cytochrome P450 subfamily (Rooney PH, et al., 2004). These organs and tissues 
contribute to idiosyncratic adverse drug reactions to some degree. Bioactivation reactions can 
also be attributed to the action of flavin-containing monoxygenase (FMO), but the functional 
groups affected by these enzymes are limited to certain nitrogen- and sulfur-containing groups 
on drug substrates (Cashman JR, 2000). In addition, monoamine oxidases (MAOs) (Gong B, et 
al., 2006) and heme-containing peroxidases (O'Brien PJ, 2000) can contribute to the 
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bioactivation of drugs. One target tissue for idiosyncratic adverse drug reactions, the bone 
marrow, is likely associated with peroxidase-catalyzed metabolic bioactivation (Ju C, et al., 
1998).  
Peroxidases play an important role in drug metabolism and can lead to the formation of 
reactive metabolites. Such reactive metabolites might give rise to cellular oxidative stress and 
protein binding to specific enzymes, and finally cause idiosyncratic adverse drug reactions and 
even cancer. The native peroxidases are heme-containing enzymes that catalyze the oxidation of 
a variety of xenobiotics using hydrogen peroxide (H2O2). Myeloperoxidase (MPO) is one of the 
members of the peroxidase family. MPO contributes 2-5% dry weight of the human neutrophil. 
In addition to neutrophils, MPO is also present in monocytes, tissue macrophages, Kupffer cells 
and bone marrow CD34+ myeloid progenitor cells (Brown KE, et al., 2001; Schattenberg DG, et 
al., 1994). MPO is a unique enzyme among all peroxidases and is most commonly associated 
with its catalysis of chloride oxidation to produce hypochlorous acid (HOCl). The high 
peroxidase activity in neutrophils has been attributed to MPO, which provides an antibacterial 
system in human body. It has been reported that secondary leukemias induced by chronic 
exposure to etoposide might be associated with MPO-catalyzed oxidation. It has been 
hypothesized that MPO-catalyzed etoposide oxidation causes radical production and reactive 
metabolite formation, further increasing cellular oxidative stress and the inactivation of 
etoposide’s molecular target, topoisomerase II. This combination of events may finally lead to 
secondary leukemias (Kagan VE, et al., 1999; Fan Y, et al., 2006). Studies, including one 
reported in this dissertation, have shown that incubation of HL60 cells, a myeloid leukemia cell 
line that contains MPO, with etoposide and hydrogen peroxide leads to the formation of GSH 
thiyl radicals and the etoposide ortho-quinone GSH adduct.  
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The Phase II enzymes are usually considered as pure detoxification pathways. These 
enzymes catalyze conjugation of xenobiotics (including drugs) and their more polar Phase I 
metabolites to hydrophilic functional groups, such as glucuronic acid, GSH and sulfate. The 
result is a dramatic decrease in the lipophilicity of drugs and an increase in their elimination. 
However, this is not always true. Conjugation pathways can result in the formation of 
electrophilic reactive metabolites (Banoglu E, 2000; Glatt H, 2000; Ritter JK, 2000). 
Glucuronidation of certain carboxylic acids results in the formation of electrophilic acyl 
glucuronides, some of which have been noted to covalently modify macromolecules. This 
covalent binding has the potential to inactive metabolic enzymes and lead to the loss of cell 
membrane integrity. The sulfation and acetylation of -OH groups on drugs can provide a good 
leaving group and therefore facilitate the formation of electrophilic reactive metabolites. 
Aromatic amine metabolites are an excellent example. Although it is less common to some 
extent, the conjugation with GSH can sometimes generate reactive metabolites (Monks TJ, et al., 
1990).  
1.3 METABOLITE IDENTIFICATION APPROACHES 
Identification of the metabolites generated by biotransformation processes is a crucial 
task in various stages of drug discovery and development. In the early drug discovery stage, it is 
necessary to identify the metabolic soft spots of compounds that show low metabolic stability. 
The result can provide information for further structure modifications of lead compounds and 
improvement of the metabolic and pharmacokinetic properties. The purpose of metabolite 
identification at this stage is to: 1) lower intrinsic clearance in order to increase systemic 
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exposure to the drug; and 2) decrease the potential for the formation of reactive metabolites 
generated by bioactivation in a particular structure/backbone/scaffold series. Identification of 
unknown metabolites in biological matrices is a difficult task due to the complexity of the 
matrices, varying in chemical structures and in concentration. Because of its superb speed, 
selectivity, and sensitivity, liquid chromatography-tandem mass spectrometry (LC-MS/MS) is 
without question the best technique for identification of unknown metabolites among a wide 
array of analytical techniques and methods (Kostiainen R, et al., 2003; Clarke NJ, et al., 2001; 
Tozuka Z, et al., 2003). The traditional metabolite identification procedure is as follows. 
Metabolites and the parent drug are separated by high performance liquid chromatography, then 
a full scan mass spectrum (MS) and a product ion (MS/MS) fragmentogram are generated by the 
mass spectrometric system. The molecular weight and chemical structure of metabolites can be 
elucidated based on such data; the latter particularly through the product ion spectra of 
metabolites. MS/MS data often can provide sufficient structure information for metabolite 
identification of candidate drugs.  Multiple stage MS experiments (MSn) are also widely used to 
generate complementary structure information (Tomer KB, 2001). In many situations, other 
parallel techniques, such as precursor ion scans, neutral loss ion scans, an accurate mass 
measurement on an instrument capable of high resolution mass spectrometry, and data-dependent 
scans can also facilitate the structure elucidation of metabolites present in a complex biological 
matrix. Furthermore, some chemical related techniques, including hydrogen/deuterium (H/D) 
exchange and chemical derivatives, can give more useful information about the chemical 
structures of metabolites. However, LC-MS cannot always determine the geometry and can only 
very rarely determine the stereochemistry of substituents within the eluting metabolites (Lindon 
JC, et al., 1997). Furthermore, it is difficult to obtain MS data for compounds that are thermally 
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labile or that are difficult to ionize in modern MS ionization sources (Dachtler M, et al., 2001). 
Therefore, nuclear magnetic resonance (NMR) is often a necessary method to be used to 
generate more detailed information, especially in regard to stereochemistry. Nowadays, modern 
two-dimensional, high field NMR can be performed in some cases on the small amounts of 
metabolites isolated from biological systems.  
In MS, the product ion scan mode is the most common scan technique used for 
metabolite identification. This scan function is available on most types of mass analyzers, such 
as triple quadrupole, 3D and linear ion trap, and ion cyclotron resonance Fourier transform (FT) 
MS systems. It also can be performed on some hybrid mass spectrometers, including quadrupole-
linear ion trap (Q-Trap) and quadrupole-time of flight (Q-TOF) MS systems. A typical product 
ion scan experiment includes three steps (Figure 1.7). The first step is the selection of the parent 
(precursor) ion of interest to be fragmented. The second step is the fragmentation of the parent 
ion by various energetic techniques, e.g., collision-induced dissociation. The third step is 
obtainment of the full scan of the product (a.k.a. daughter) ions obtained by fragmentation in the 
second step. The interpretation of the product ion spectra (MS/MS data) usually provides enough 
data to intelligently propose chemical structures of metabolites generated by biotransformation. 
In addition to the product scan mode, there are other scan techniques that can be 
performed, but only on some types of instruments. Precursor ion scan mode and neutral loss ion 
scan mode are two of the relatively commonly used scan techniques. Usually, these two ion scan 
modes can be performed on a triple quadrupole mass spectrometer. They are powerful tools for 
detecting metabolites in complex biological matrix. If a drug can produce a characteristic neutral 
product ion that corresponds to a specific structural feature after fragmentation, that specific 
neutral loss can be used for detecting metabolites related to the 
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Figure 1.7 Different ion scan modes in triple quadrupole mass analyzer: A. product ion scan; B. 
neutral loss ion scan; C. precursor ion scan. (multiple arrows: full scan mode; single arrow: 
selective ion mode, arrows in Q2: collision induced dissociation.) 
 
parent drug. A typical neutral loss ion scan experiment (Figure 1.7) performed on a triple 
quadrupole mass spectrometer is set to full scan both in Q1 and Q3, but the mass difference of 
Q1 and Q3 full scan is fixed. This difference corresponds to the neutral loss of the molecular ion 
during collision-induced dissociation. Therefore, only those molecular ions that give rise to this 
common neutral loss are recorded in the final mass spectral data file. The neutral loss scan mode 
is widely used in the detection of Phase II metabolites, which usually generate neutral fragments 
during fragmentation. For example, GSH conjugates and adducts show a neutral loss of 129, 
glucuronide conjugates give a neutral loss of 176, and sulfate conjugates show a neutral loss of 
80 (Prakash C, et al., 1997; Davoine C, et al., 2005). The precursor ion scan mode can also be 
 15 
used as a powerful tool for detecting target metabolites if the drug produces a characteristic 
fragment ion corresponding to a specific chemical structure feature after collision-induced 
dissociation. In a precursor scan experiment (Figure 1.7), Q1 is set to full scan mode and Q3 is 
set to select the product ion scan in which only a characteristic fragment ion can be detected. 
Thus, precursor ions generating this common fragment ion can be recorded in the MS/MS 
analytical data file. Precursor ion scanning is very useful in discovery stages where radiolabeled 
compounds are not available. Neutral loss ion scan and precursor ion scan can dramatically 
reduce the consumption of samples and increase analytical efficiency. 
MS/MS scanning (MS2) is usually referred to as the first stage product ion scan. Further 
fragmentation of select product ions produced by MS2 is called MS3. Continuous fragmentation 
of product ions from the previous stage leads to what are known as MSn experiment and the 
resulting multiple stage mass spectra. A scheme of multiple stage ion scanning performed in an 
ion trap mass analyzer is illustrated in Figure 1.8. The MSn  results are a very useful means for 
structure elucidation of unknown metabolites because such results can not only provide a 
convenient way for fragment assignment, but also give rise to a wealth of information about 
chemical structures of metabolites in a single analysis. This type of scan is not available to all 
kinds of mass analyzers. Only those instruments that trap ions, such as 3D and linear ion traps 
(including the hybrid quadrupole-ion trap (Q-TRAP)), and FT-ion cyclotron resonance (FT-ICR) 
systems, can perform these multiple stage ion scans. This method is very useful to determine the 
sites of biotransformation. In some cases, it can also differentiate the chemical structures of the 
fragment ions that own the same mass charge ratio. Thus, it is very helpful to run multiple stage 
ion scan experiment when an MS/MS scan can not give rise to enough information for structure 
elucidation. 
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Figure 1.8 The scheme of a MS3 experiment in ion trap. The experiment is initiated by 
the collection of the ion currant, followed by the isolation of the parent ion, excitation of the 
parent ion, isolation of the fragment ion, excitation of the fragment ion and the ejection of the 
secondary fragment ions generated by the secondary excitation. 
 
Accurate mass measurement can be crucial in distinguishing essentially isobaric 
molecular ions and in assigning fragment ions for elucidation of fragmentation mechanisms (Ma 
S, et al., 2006). Accurate mass measurement can help confirm the molecular formula of both 
parent ions and fragment ions under investigation. Accurate mass measurement is usually 
performed with several types of mass analyzers owning higher mass accuracy, e.g., those 
containing TOF and FT-ICR analyzers. This experiment can also performed with hybrid mass 
analyzers, like linear ion trap-FT-ICR or QqTOF systems (Sanders M, et al., 2006).  
Hydrogen/deuterium exchange experiments are a strategy widely used for elucidation of 
mass spectral fragmentation mechanisms (Ma S, et al., 2006). The biotransformation of drugs 
usually introduces polar functional group such, as hydroxyls, or alters some functional groups, 
such as amines. The biotransformation will lead to a number of exchangeable hydrogen atoms, 
which can be exchanged with deuterium. H/D exchange experiments can in fact be performed 
on-line when the water in the reversed phase HPLC mobile phase is replaced by heavy, 
deuterium-containing water (2H2O, a.k.a. D2O). Hydroxylation of the parent drug introduces an 
additional exchangeable hydrogen atom, which can be detected by H/D exchange experiments 
on-line. The more the hydroxyl groups in chemical structures of metabolites, the higher purity of 
D2O required. 
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1.4 METABOLIC STABILITY 
Drug development is a time-consuming process. The average development time of a new 
drug is around twelve years, and the cost in 2004 was approximately $900 million (Kola I, et al., 
2004). The major reason for the failures in drug development is poor metabolic and 
pharmacokinetic properties (Kola I, et al., 2004). Previously, drug metabolism studies were 
performed at a late stage of drug development, such as in clinical studies. Nowadays, 
pharmaceutical companies have introduced many new methods to improve the metabolic and 
pharmacokinetic properties at an earlier stage in drug development process, and even at drug 
discovery phase. The study of in vitro metabolic stability is one of them (Plant N, 2004).   
In vitro models to study drug metabolic stability include incubations of lead agents with 
liver microsomes and/or hepatocytes. Liver microsomes are the most common tool used to study 
metabolic stability. Compared with hepatocytes, microsomes are very stable during prolonged 
storage and more convenient to use. Usually, pooled liver microsomes from different donors are 
used in order to minimize the difference of enzyme activity from each donor. In addition to CYP 
enzymes, there are other enzymes present in microsomes, such as flavin-containing 
monoxygenase (FMO) and UDP-glucuronosyltransferase (UGT). Microsomal systems have 
several advantages, such as easy use and preparation, a maintenance-free nature, high enzyme 
concentrations, and high stability. Hepatocytes are also valuable for metabolic stability studies. 
This model includes all Phase I and Phase II enzymes in liver, as well as the co-factors for 
enzyme activities. However, the availability of fresh hepatocytes and the short lifetimes of the 
cells hamper the widespread deployment of this model. Although in vitro models can minimize 
the inter-species difference in drug metabolism enzymes, it is important to keep in mind that they 
represent a simplistic view of the in vivo systems in which drug biotransformation takes place. 
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Therefore, researchers must pay attention to this point when predictions of drug metabolism in 
vivo are made with data collected from in vitro systems.  
 Metabolic stability studies using liver microsomes as the model are performed based on 
the following assumptions: 1) in vitro metabolism represents the metabolism in vivo; 2) the liver 
is the major organ for drug metabolism; and 3) the major elimination pathway of oxidative 
metabolism is mediated in the first step by CYP enzymes. In the present studies, the in vitro half-
life approach utilizing liver microsomes was used to evaluate the metabolic stability of 
compounds. This approach, reported in Chapter 5, is the most widely used model for in vitro 
metabolism because of its simplicity. In this method, the natural log scale of the percentage of 
parent compound remaining versus time is plotted. The percentage of parent compound 
remaining is calculated by comparing the amount of compound remaining at different times to 
the amount of compound present at 0 min (t = 0). The slope of the line resulting from regression 
analysis is –k, and the half life (t1/2) is calculated using the formula  
 
t1/2 = 0.693/k 
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1.5 ETOPOSIDE, DISCODERMOLIDE, AND DICTYOSTATIN 
Etoposide. Etoposide (a.k.a. VP-16) is one of the most widely used anticancer agents. It 
is a semi-synthetic derivative of a natural product from Podophyllum peltatum (Pommier Y, et 
al., 1985).  
The anticancer mechanism of etoposide is based on its inhibitory effects on the DNA 
rejoining catalyzed by the ATP-utilizing enzyme topoisomerase IIα (Topo II) (Pommier Y, et al., 
1985). Topo II is an essential DNA binding protein responsible for double strand cleavage of 
DNA. It allows the passage of one DNA strand across another to relieve torsional stress during 
replication and transcription, and allows for separation of daughter DNA strands during mitosis. 
Topo II is a target for a number of clinically effective anticancer agents. These drugs interfere 
with topo II’s activity by stabilizing topo II/DNA binding in a covalent cleavable complex, which 
prevents subsequent reannealing activity and leads to sustained DNA strand breaks. 
Numerous groups have reported in the past ten years that the same treatment schedules 
associated with the impressive clinical efficacy of VP-16 are also associated with an increased 
risk of secondary treatment-related acute myeloid leukemia (t-AML) (Pui CH, et al., 2000; 
Winick NJ, et al., 1993). t-AML is characterized by distinct translocations involving the 
chromosome 11q23 region. An 8.3-kb breakpoint cluster region of the MLL gene that 
encompasses exons 5 through 11 has been found to be associated with myeloid leukemia arising 
subsequent to treatment with topo II inhibitors such as VP-16 (Pui CH, et al., 1989; Pedersen-
Bjergaard J, et al., 1994). The MLL gene encodes a 3969 amino acid protein whose function 
likely regulates transcription of genes important in hematopoietic differentiation. In t-AML, the 
MLL gene is recombined with a variety of chromosomal partners.  MLL partners with over 40 
different genes to create leukemogenic gene fusions. (Eguchi M, et al, 2005). Each translocation 
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yields in-frame fusions in the derivative chromosome 11, likely resulting in functional chimeric 
proteins. Hence, 11q23 translocations of MLL are considered to be likely causative for t-AML 
(Popovic R, et al., 2005). 
Chromosome band 11q23 translocation breakpoints within the centromeric portion of the 
MLL breakpoint cluster region have been identified to be in close proximity to etoposide-
induced Topo II cleavage sites (Aplan PD, et al., 1996). A double strand DNA cleavage site has 
been identified within the telomeric portion of the MLL breakpoint cluster region in malignant 
cell lines and in normal peripheral blood lymphocytes treated with etoposide (Nasr F, et al., 
1997). These drug-induced DNA cleavage sites map to the same region as a consensus Topo II 
cleavage site within the MLL breakpoint cluster region. These investigations suggest that site-
specific cleavage within the MLL breakpoint cluster region induced by Topo II inhibitors may be 
an early marker of apoptosis, or may lead to translocations and secondary leukemias (Ng A, et 
al., 2000). These results imply that myeloid progenitor cells may be unusually susceptible targets 
for the leukemogenic effects of etoposide. 
In summary, etoposide is converted to several metabolites, such as the hydroxyl acid, the 
cis-lactone, the E-ring catechol, and a glucuronide (Relling MV, et al., 1994; Watanabe Y, et al., 
2003). Some oxidative enzymes, e.g., peroxidases, tyrosinase and cytochrome P450 isozymes, 
can also generate intermediate phenoxyl radical species leading to the catechol, the ortho-
quinone and semiquinone metabolites of etoposide. Covalent reaction of etoposide ortho-
quinone with DNA and protein has been reported in isolated microsomal or DNA preparations 
(Haim N, et al., 1987). In addition, ortho-quinone-mediated inactivation of single and double 
stranded DNA has been associated with direct adduct formation, and has been demonstrated to 
induce Topo II-mediated DNA cleavage (van Maanen JM, et al., 1985). Therefore, etoposide 
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ortho-quinone may play an important role in etoposide’s action, as well as toxicities. Its 
overproduction in MPO+ cells may make this stem cell population particularly susceptible to the 
recombinogenic events related to MLL translocations. 
Previous studies show that there is a correlation between adduct formation, Topo II 
inhibition and cytotoxicity for the ortho-quinone, and the results suggest that Topo II poisoning 
by the ortho-quinone is due to chemical modification of Topo II (Gantchev TG, et al., 1998). In 
the present studies, direct chemical adduction between etoposide ortho-quinone and cysteine 
sulfhydryls was assessed, as was the formation of the metabolite and adducts in human cells 
containing MPO. The results provided detailed information about the production of this 
metabolite in hematopoietic cells, and perhaps a better understanding of the mechanism by which 
etoposide therapy leads to the formation of secondary leukemias. 
 
Discodermolide. Microtubules are an important target for cancer therapy, e.g., a 
microtubule stabilizer, paclitaxel, has been used successfully in the treatment of different type of 
cancers, particularly solid tumors (Flechon A, et al. 2006). Microtubules are one of the principal 
components of the cytoskeleton, and the dynamic structure of microtubules, provides a 
somewhat cancer -selective means of treatment by agents that alter microtubule dynamics. 
Microtubules are composed of monomers containing a heterodimeric protein, tubulin, which 
includes the subunits α-tubulin and β-tubulin. Microtubules are polar structures with two distinct 
ends: a fast-growing plus end and a slow-growing minus end. This polarity is an important 
consideration in determining the direction of movement of motor proteins along microtubules 
(Rungger-Brandle E, et al., 1983). The assembly and disassembly of microtubules is a dynamic 
progress. During or shortly after polymerization, the GTP bound to β-tubulin is hydrolyzed to 
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GDP and this GTP hydrolysis weakens the binding affinity of tubulin for adjacent molecules, 
thereby favoring depolymerization and resulting in the dynamic behavior of microtubules 
(Mareel MM, et al., 1985). Microtubules are particularly critical for mitosis, so drugs that affect 
microtubule assembly are powerful weapons in the treatment of cancer. 
Paclitaxel was the first microtubule stabilizing agent on the market. It has been used for 
over a decade. It is isolated from the extracts of the bark of the pacific yew, Taxus brevifolia, and 
was initially identified as a cytotoxic agent (Wani MC, et al., 1971). Although paclitaxel is one 
of the most effective chemotherapeutic drugs, it has several limitations: 1) it is susceptible to 
several forms of mechanism-based drug resistance, such as the efflux pump P-glycoprotein (Pgp; 
a.k.a. ABCB1)-mediated drug resistance and selection of mutant or overexpression of unaffected 
β-tubulin (Iwahana M, et al., 1998; Fukushima M, et al., 2000); 2) the aqueous solubility of 
paclitaxel is poor, ca. 7 µM (Rowinsky EK, 1997); and 3) its structural complexity makes it 
difficult to synthesize from readily available and inexpensive raw materials.  
To overcome these drawbacks, new generation microtubule stabilizing agents with 
increased efficacy and/or better synthetic accessibility have been sought. One of the most 
interesting drugs in this regard is discodermolide. (+)-Discodermolide was initially isolated from 
a marine sponge, Discodermia dissoluta, and was incorrectly identified as an 
immunosuppressive agent (Gunasekera SP, et al., 1990). Later, it was demonstrated that this 
compound could cause cell cycle arrest at mitosis in a variety of cell lines at low concentrations, 
ranging from 3 to 80 nM, and treated cells that survived (i.e., did not apoptose) eventually exited 
mitosis with micronuclei (Hung DT, et al., 1996). Isolated tubulin treated with discodermolide 
forms abnormal microtubules, and these microtubules show increased stability against cold-
induced depolymerization (ter Haar E, et al., 1996). Discodermolide has been found to bind 
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either to the same site on microtubules as paclitaxel or to an overlapping site, and 
discodermolide’s affinity for the same site as paclitaxel is higher (Kowalski, RJ, et al. 1997). It is 
believed that discodermolide can stabilize mitotic spindle microtubule dynamics and inhibit the 
rate and extent of shortening instead of changing the amount of polymerized tubulin (ter Haar E, 
et al., 1996). Compared with paclitaxel, discodermolide is substantially more potent in most cell 
lines tested (Mani S, et al., 2004). It is not a substrate of P-gp (Kowalski RJ, et al., 1997).  It is 
also able to induce apoptosis in cell lines that are resistant to paclitaxel due to mutations in β-
tubulin, while another type of new microtubule stabilizers, the epothilones, do not (Kowalski RJ, 
et al., 1997). Intriguingly, the combination of paclitaxel with discodermolide demonstrates 
synergistic effects in enhancement of cell death, suppression of microtubule dynamics and 
induction of mitotic arrest, and this synergic effect was not observed for combinations of 
paclitaxel with epothilones (Honore et al., 2004; Hamel E, et al., 2006). Discodermolide has a 
somewhat simpler chemical structure than does paclitaxel. Total syntheses of discodermolide has 
been reported by several groups (e.g., Paterson I I, et al., 2000; Smith AB, et al., 2005; Harried 
SS, et al., 2003) and it has been produced by full synthesis at large scale (Francavilla C, et al., 
2003). The aqueous solubility of discodermolide is also much higher than that of paclitaxel 
(Kowalski RJ, et al., 1997).  
However, discodermolide has some features that impact its clinical development. Its 
maximum tolerated dose in rats is only ca. 1.0 mg/kg (Mita C, et al., 2003). Preclinical ADME 
studies show that discodermolide is rapidly cleared from plasma (Mita C, et al., 2003). In order 
to increase metabolic stability mediated by CYP enzymes, decrease the dose of administered, 
and therefore decrease the toxicity of discodermolide, its metabolism by pooled human liver 
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microsomes was examined here. Several metabolites were detected in vitro, and a soft spot for 
biotransformation was identified. 
 
Dictyostatin. Marine organisms are proving to be a rich source of bioactive secondary 
metabolites with potential anticancer properties (Gunasekera SP, et al., 1990). In fact, many 
microtubule stabilizing agents, such as discodermolide, eleutherobin and laulimalide, come from 
extracts of marine organisms. Although their chemical structures share little similarities, all of 
them have a very similar mechanism of action.  
 A novel 22-membered macrocyclic lactone, (–)-dictyostatin, was initially isolated from a 
Republic of Maldives marine sponge of Spongia species in 1994 and found to strongly inhibit the 
growth of murine P388 lymphocytic leukemia cells (Pettit GR, et al., 1994). Later, dictyostatin 
was found to arrest cells in the G2/M phase of the cell cycle and to induce the polymerization of 
tubulin in vitro. Like discodermolide, the microtubules induced by dictyostatin are resistant to 
cold temperatures (Isbrucker RA, et al., 2003). Dictyostatin and discodermolide share a high 
degree of homology in their chemical structures. Total synthesis of dictyostatin has recently been 
reported by several groups (Shin Y, et al., 2004; Paterson I, et al., 2004; O'Neil GW, et al., 2006; 
Ramachandran PV, et al., 2007). Similar to discodermolide, dictyostatin is also highly potent 
against paclitaxel-resistant human cancer cell lines overexpressing active P-glycoprotein 
(Isbrucker RA, et al., 2003). The studies described in this dissertation indicate that dictyostatin is 
metabolically unstable, albeit less so than discodermolide, and is extensively transformed by 
pooled human liver microsomes. It was no surprise that the same soft spot as found in 
discodermolide was found for biotransformation of dictyostatin. The data discovered in this work 
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may prove useful in designing analogues with improved metabolic and pharmacokinetic 
properties. 
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2.1 ABSTRACT 
Etoposide is a widely used antineoplastic agent that has provided great success in the 
treatment of childhood leukemias and other malignancies. Unfortunately, its use is associated 
with increased risk of development of secondary acute myelogenous leukemias involving 
translocations at the MLL gene in chromosome band 11q23. Previous studies showed that the 
phenoxyl radical of etoposide can be generated by myeloperoxidase (MPO), an enzyme 
prevalent in myeloid progenitor cells that can derive myelogenous leukemias. Disproportionation 
of this radical leads to formation of the redox active etoposide ortho-quinone metabolite. We 
hypothesized that etoposide ortho-quinone could be formed in myeloid progenitor cells and 
might contribute to the development of treatment-related secondary leukemias. Etoposide ortho-
quinone is an inherently unstable compound and readily reacts with glutathione in aqueous 
media without any requirement for catalytic assistance from glutathione S-transferase. We 
looked for the presence of its glutathione adduct as an indicator of etoposide ortho-quinone in 
cells. MPO-expressing human myeloid leukemia HL60 cells were treated with etoposide for 0.5 
h in the presence and absence of the cosubstrate of MPO, hydrogen peroxide. Cell lysates and 
medium were analyzed by LC-ESI-ion trap-MS and MS/MS, which yielded clear evidence of the 
intracellular formation of the etoposide ortho-quinone-glutathione adduct. A stable isotope-
labeled form of the GSH adduct was synthesized and employed as an isotope dilution internal 
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standard in LC-ESI-quadrupole-MS analyses. The glutathione adduct level was dependent on the 
concentration of etoposide added to the cells. More importantly, the formation of the glutathione 
adduct was significantly suppressed by the pretreatment of HL60 cells with the heme synthesis 
inhibitor succinylacetone (p < 0.001), which resulted in a decreased level and activity of MPO. 
These results are consistent with the idea that MPO is responsible for the conversion of etoposide 
to its ortho-quinone in these cells. 
2.2 INTRODUCTION 
Etoposide is one of the several widely used cancer chemotherapeutic DNA topoisomerase 
II (Topo II) inhibitors. It is a semisynthetic derivative of the natural product podophyllotoxin, 
which is one compound present in an extract from the plants Podophyllum peltatum and 
Podophyllum emodi. Etoposide inhibits Topo II-catalyzed DNA rejoining and stabilizes the 
enzyme-DNA cleavage complex (Pommier Y, et al., 1985). Several metabolites of etoposide 
have been identified in humans, such as its hydroxyl acid, cis-(picro)lactone, catechol, and 
glucuronide (Stewart CF, 1994). It has been reported that etoposide catechol formation is 
catalyzed by CYP3A4 and CYP3A5 (Relling MV, et al., 1994; Zhuo X, et al., 2004; Zheng N, et 
al., 2004)  and that of the glucuronide by UGT1A1 (Watanabe Y, et al., 2003). Etoposide and its 
catechol also can be converted by one-electron (1-e–) oxidation to their respective phenoxyl 
radicals (i.e., the semiquinone from the catechol) by peroxidases and prostaglandin synthetase 
(Haim N, et al., 1986; Haim N, et al., 1987; Van Maanen JM, et al. 1988; Kagan VE, et al., 
2001). An additional 1-e- oxidation or disproportionation of these phenoxyl radical species can 
convert them to the etoposide ortho-quinone metabolite. Formation of this etoposide metabolite 
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has recently been demonstrated in humans (Zhuo X, et al., 2004; Zheng N, et al., 2004). Use of 
etoposide in the clinic is accompanied by an increased risk of development of secondary 
leukemias specifically treatment-related acute myeloid leukemia (t-AML) characterized by 
translocations of the MLL gene involving the chromosome 11q23 region (Felix CA, 1998; Felix 
CA, 2001; Shearer P, et al., 2001; Wierecky J, et al., 2005; Josting A, et al., 2003). Despite this 
recognized epidemiological link, the mechanism(s) behind the high susceptibility of myeloid 
progenitors, such as CD34+ cells, to the leukemogenic effects of etoposide remains unclear 
(Libura J, et al., 2005). It is not known why etoposide preferentially causes myeloid leukemias 
but not other types of leukemias.  
Because CD34+ myeloid precursor cells in early stages of maturation contain relatively 
high levels of the 1-e- oxidizing enzyme myeloperoxidase (MPO) (Strobl H, et al., 1993), we 
previously hypothesized that oxidative activation of the phenolic moiety of etoposide by MPO 
may be responsible for converting this drug to a more genotoxic and carcinogenic species 
(Kagan VE, et al., 2001). In support of this hypothesis, we used both purified MPO and MPO-
rich HL60 myeloid leukemia cells as surrogates for CD34+ cells to directly demonstrate (i) 1-e- 
metabolic oxidation of etoposide to its phenoxyl radical (etoposide-O ) accompanied by 
generation of thiyl radicals and oxidation of protein sulfhydryl groups and (ii) MPO-dependent 
enhancement of etoposide-induced Topo II-DNA complex formation (Kagan VE, et al., 2001). 
Both the formation of etoposide-O  and the increase in etoposide activity were prevented by use 
of MPO inhibitors and nutritional antioxidants, such as the free radical scavenger vitamin C and 
analogues of vitamin E (Kagan VE, et al., 2001; Kagan VE, et al., 1998). In addition, inhibition 
of MPO activity in HL60 cells was associated with decreased etoposide-induced DNA strand 
breakage, diminished oxidative DNA damage, and reduced cleavage of the MLL gene known to 
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be associated with t-AML (Yalowich JC, et al., 2004). These results led to the idea that 
nutritional strategies can be utilized to minimize etoposide conversion to etoposide-O  and to 
possibly prevent t-AML (Kagan VE, et al., 1999; Maellaro E, et al., 1996; Kagan VE, et al., 
1994; Kagan VE, et al., 1998; Tyurina YY, et al., 1995). Because MPO may also catalyze the 
formation of a 2-e- oxidation product of etoposide, the chemically reactive metabolite etoposide 
ortho-quinone (Maanen JMS, et al., 1988), we now further posit that this metabolite of etoposide 
may contribute to the genotoxic and leukemogenic action of etoposide. It is known that oxidative 
formation of 8-hydroxy-2'-deoxyguanine and endonuclease generation of apurinic sites on DNA 
(Chung MH, et al., 1991; Demple B, et al., 1994) can result in poisoning of Topo II and 
activation of DNA double strand cleavage (Kingma PS, et al., 1997; Sabourin M, et al., 2000). 
Hence, MPO-catalyzed oxidation of etoposide to its ortho-quinone may potentiate Topo II-
mediated recombination events through redox-cycling mechanisms.  
To test this hypothesis, it is first necessary to determine if the etoposide ortho-quinone is 
formed in myeloid lineage cells. In the present work, we demonstrate that etoposide ortho-
quinone is produced in myeloid HL60 cells and readily forms conjugates with GSH and that 
these conjugates are detectable and quantifiable. Furthermore, we show that the formation of the 
GSH adduct depends on the MPO activity in the cells.  
To further understand the mechanism of reaction with GSH in vivo, we required 
authentic reference metabolites, as well as an analytical method to quantify these compounds. 
We report the synthesis and characterization of these compounds, as well as the measurement of 
their metabolically generated forms in HL60 cells exposed to etoposide. The data obtained 
should facilitate future studies of therapy-related secondary leukemias and the assessment of the 
importance of MPO-catalyzed oxidative activation of etoposide in this process. 
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2.3 MATERIALS AND METHODS 
Instruments. 1H and 13C NMR spectra were obtained on a Varian Mercury 400 
spectrometer operating at 400 or 100 MHz using the residual proton (2.54 or 7.26 ppm) or 13C 
(44.5 or 77.4 ppm) signals from the deuterated solvent, d6-DMSO or CDCl3, as the internal 
reference. Infrared spectra were recorded on a Nicolet Avatar 360 FT-IR spectrophotometer. 
MALDI-TOF and MALDI-TOF/TOF mass spectra were obtained using -cyano-4-
hydroxycinnamic acid as the matrix on an Applied Biosystems 4700 instrument. Synthesized 
compounds were purified over C18 columns on a Dionex Summit HPLC. LC-MS/MS analyses 
were performed on a ThermoFinnigan Deca XP Plus ion trap system equipped with a 
ThermoFinnigan Surveyor HPLC. Stable isotope dilution quantitative studies were performed by 
LC-MS on a ThermoFinnigan MSQ single quadrupole system. UV spectra were obtained on a 
Shimadzu UV160U spectrophotometer.  
Chemicals. Etoposide was obtained from Polymed Therapeutics Inc. (Houston, TX). 
[13C215N-Gly]Glutathione was purchased from Toronto Research Chemicals, Inc. (North York, 
ON, Canada). Triton X-100 (t-octylphenoxypolyethoxyethanol) was from Bio-Rad Laboratories 
(Richmond, CA). Acetonitrile (HPLC grade) and sodium periodate were from Fisher Scientific. 
Water was deionized and distilled from KMnO4. Stock solutions were stored at –20 C. Other 
reagents were from Sigma Chemical Co. (St. Louis, MO) and were of the highest available 
quality.  
Synthesis of Etoposide ortho-Quinone and Catechol. The target compounds were 
prepared by a previously reported method (Pang S, et al., 2001) with minor modifications. 
Etoposide (390 mg, 663 mol) was dissolved in dioxane (7.2 mL) and H2O (14.1 mL). NaIO4 
(4.2 mL of a 0.5 M aqueous solution) was added with stirring. The reaction mixture stirred in the 
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dark at 10 ± 4 C for 4 h and then treated to saturation with solid (NH4)2SO4. The resulting 
solution was extracted with CH2Cl2 (1 × 10 mL and then 5 × 5 mL). The organic phases were 
combined, washed with H2O (5 × 5 mL), dried with MgSO4, and filtered. After evaporation, the 
residue was recrystallized from CH2Cl2/diethyl ether. The solid was filtered, washed with diethyl 
ether three times, and taken to complete dryness under vacuum to give 304 mg (80%) of the 
product as a purple powder, which was stored protected from light; mp 200-210 C. 1H NMR 
(CDCl3): 4.15 (2H, m), 4.60 (1H, d, J = 7.7 Hz), 4.70 (1H, q, J = 5.0 Hz), 4.90 (1H, d, J = 3.4 
Hz), 5.98 (2H, d, J = 1.0 Hz). MS (ESI) m/z calculated for [M+H]+ C29H29O13 (centroid), 573.5; 
found, 573.5.  
The catechol was prepared as follows. Etoposide ortho-quinone (148 mg, 253 µmol) was 
dissolved in dioxane (2.5 mL) and H2O (5 mL) under nitrogen and cooled to 0 C. NaBH4 (1 M 
in THF, 1.4 mL) was added dropwise with stirring. After 10 min, 0.6 mL of 1 M HCl was added 
to quench the reaction. The catechol was extracted with CH2Cl2 (5 × 5 mL), the combined 
organic extracts were washed with H2O, dried with Mg2SO4, and filtered, and the solvent was 
evaporated. The resulting residue was crystallized with CH2Cl2/diethyl ether to give a white 
powder in 60% yield; mp 230-231 C. 1H NMR (CDCl3): 4.15 (2H, m), 4.60 (1H, d, J = 7.7 
Hz), 4.70 (1H, q, J = 5.0 Hz), 5.98 (2H, d, J = 1.0 Hz). MS (ESI) m/z calculated for [M + H]+ 
C29H31O13 (centroid), 575.5; found, 575.5.  
Synthesis of Etoposide ortho-Quinone-Glutathione Adduct. Etoposide ortho-quinone 
(114.5 mg, 200 µmol) was dissolved in dioxane (2.5 mL) and mixed with GSH (61.5 mg, 200 
µmol) dissolved in 5 mL of H2O. The mixture was stirred in the dark at room temperature for 4 
h. The resulting solution was lyophilized to give a pale yellow powder (170 mg, 96% crude 
yield). Purification was conducted by HPLC over a Vydac C4 column (250 mm × 10 mm, 300 Å 
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pore size, 5 µm particle size) using 254 nm as the primary monitoring wavelength (4:1 
H2O/CH3CN, flow rate of 1.5 mL/min). The HPLC analysis showed the crude product to be of 
90% purity. The fractions containing the desired product were combined and lyophilized to give 
a white solid; mp 185-190 C. 1H NMR (d6-DMSO): 1.39 (3H, d, J = 5.0 Hz), 2.05 (2H, m), 
2.90 (2H, m), 3.42 (1H, t, J = 7.6 Hz), 3.68 (3H, m), 3.75 (3H, s), 4.15 (2H, m), 4.30 (1H, m), 
4.68 (1H, d, J = 7.6 Hz), 4.76 (1H, q, J = 5.0 Hz), 4.95 (1H, d, J = 3.4 Hz), 6.06 (2H, d, J = 1.0 
Hz), 6.35 (1H, s), 6.55 (1H, s), 6.95 (1H, s), 7.03 (1H, s). 13C NMR (d6-DMSO): 21.3, 27.7, 
32.5, 42.2, 53.1, 53.9, 61.1, 63.7, 63.8, 66.1, 66.7, 67.3, 70.9, 73.4, 91.7, 99.6, 169.0, 171.4, 
172.0, 172.9. IR cm-1 (KBr): 3293 (H-bond OH), 3056, 2925, 1725 (C=O), 1650 (C=C), 1534 
(C=C). HRMS (MALDI) m/z calculated for [M + H]+ C38H46N3O19S, 880.2446; found, 
880.2373. MALDI-TOF-TOF-MS of the quasimolecular ion (m/z 880.3 ± 30 ppm) yielded 
fragment ions of m/z 805.2 [M+H–Gly]+, m/z 751.2 [M+H–Glu]+, m/z 674.1 [M+H–206]+, and 
m/z 545.1 [M+H–Glu–206]+.  
A similar procedure was used at the 3 mol scale for the preparation of the stable isotope-
labeled [13C2,15N-Gly]glutathione adduct of etoposide ortho-quinone. HRMS (positive ion 
MALDI) m/z calculated for [M+H]+ 12C3313C2H4614N215NO19S, 883.2484; found, 883.2383. 
MALDI-TOF/TOF-MS/MS analysis of the quasimolecular ion (m/z 883.3 ± 30 ppm) yielded 
fragment ions of m/z 754.2 [M+H–Glu]+, m/z 677.1 [M+H–206]+ and m/z 548.1 [M+H–Glu– 
206]+.  
Cell Culture. HL60 cells were cultured in phenol red-containing RPMI 1640 medium 
with 15% fetal bovine serum at 37 C under a 5% CO2, humidified atmosphere. The density of 
cells (in log-phase growth) at the time of experimentation was 5 × 105 cells/mL.  
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MPO Activity of HL60 Cells. The MPO activity of HL60 cells was determined using 
the guaiacol oxidation assay (Pinnix IB, et al., 1994). Cells were pelleted by centrifugation and 
then suspended in L1210 buffer (25 mM HEPES and 5 mM NaH2PO4, pH 7.4, containing 10 
mM glucose, 115 mM NaCl, 5 mM KCl, and 1 mM MgCl2) to a concentration of 1 × 107 
cells/mL. The cell suspension was frozen at –20 C and subsequently thawed. The lysate from 5 
× 106 cells was added to a reaction mixture containing 3.75 mM 3-amino-1,2,4-triazole, 0.02% 
(v/v) cetyltrimethylammonium bromide, 100 M PMSF, 0.1% (v/v) Triton X-100, 13 mM 
guaiacol, and 670 µM H2O2. The activity was monitored by changes in absorption at 470 nm ( 470 
= 26.6 mM–1cm–1). On average, the MPO activity of cell homogenates was about 40 nmol of 
guaiacol oxidized /min/1 × 106 cells at 25 C.  
For suppression of MPO activity, HL60 cells were incubated for 68 h with 
succinylacetone (200 µM) dissolved in RPMI 1640 medium. Cell viability was determined 
microscopically by Trypan blue dye exclusion to be 98%, and MPO activity was determined by 
UV spectrophotometry as outlined above.  
Western Blotting for MPO. Whole cell lysates were prepared from pelleted HL60 cells 
(2 × 107) and K562 cells (5 × 106) by the addition of 2× SDS-polyacrylamide gel electrophoresis 
sample buffer [50 mM Tris-HCL, pH 6.8, 1% (w/v) SDS, 10% (v/v) glycerol, and 0.5% (v/v) 2-
mercaptoethanol], followed by boiling for 5 min and brief sonication. Protein samples of HL60 
(2 µg) and of K562 (40 µg) cell lysate were resolved using 10% (w/v) SDS-polyacrylamide gel 
electrophoresis and then transferred to nitrocellulose. Visual inspection of Ponceau S-stained 
nitrocellulose membranes was used to ensure equivalent loading/transfer of the lysates. 
Membranes were blocked with nonfat dry milk (3% w/v) in PBS containing 0.05% (w/v) Tween 
20 and then incubated with 1:40000 dilutions of primary rabbit anti-MPO antibodies kindly 
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provided by Dr. William Nauseef, University of Iowa School of Medicine. The secondary 
donkey anti-rabbit antibody used at 1:20000 dilution was purchased from Jackson Immuno-
Research Laboratories (Westgrove, PA). Bound secondary antibody was detected using 
enhanced chemiluminescence (NEN, Boston, MA).  
Treatment of HL60 Cells with Etoposide and H2O2. HL60 cells, with or without 
previous succinylacetone pretreatment, at a density of 1 × 106 cells/mL in L1210 buffer were 
incubated in the presence or absence of the given concentrations of etoposide (predissolved in 
DMSO, the final concentration of which was 0.1%) and H2O2 for 30 min at 37 C in aerobic 
conditions in the dark. Cells were then harvested by centrifugation at 3000 rpm for 4 min, and 
the pellet was frozen at -80 C. After thawing, etoposide and its derivatives were extracted with 
100 L of cold MeOH.  
Determination of Glutathione Adduct in HL60 Cells Using LC-MS/MS. The extract 
was injected into a ThermoFinnigan Surveyor HPLC equipped with a prepacked Pico Frit C18 
column (7.5 m × 10 cm, New Objectives, Inc.) and segregated at a flow rate of 160 nL/min 
beginning with 19:1 H2O-CH3CN containing 0.1% (v/v) aqueous HCO2H that was changed 
linearly over 25 min to 1:1 H2O-CH3CN containing 0.1% (v/v) aqueous HCO2H. The effluent 
was monitored for positive ions in the m/z 400-1800 range with a ThermoFinnigan LCQ DECA 
XP Plus ion trap mass spectrometer fitted with a New Objectives nanoelectrospray ionization 
source. The spray voltage was 1.43 kV. The capillary temperature was 180 C, and the capillary 
voltage was 3.3 V. Ion trap MS/MS analyses for the parent ion of the GSH adduct at m/z 880.0 
were performed with 35% normalized collision energy. Data were processed with Xcalibur 
software.  
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Quantification of the Glutathione Adduct in HL60 Cells Using LC-MS. Cell extracts 
were treated with the synthetic etoposide ortho-quinone-[13C2,15N-Gly]glutathione adduct and 
analyzed by LC-ESI-MS on a Thermo-Finnigan MSQ single quadrupole system. Analyses were 
performed in selected ion monitoring (SIM) mode with an ionization voltage of 3.2 kV and cone 
voltage of 60 V at a temperature of 300 K. Separation was performed using a Waters YMC 
ODSAQ column (2.0 mm × 150 mm) with a mobile phase of 4:1 H2O-CH3CN containing 0.1% 
(v/v) HCO2H at a flow rate of 0.2 mL/min, giving a pressure of 2500 psi. The injection volume 
was 10 L.  
Statistical Analysis. The means of the GSH adduct formed between two groups (plus or 
minus succinylacetone treatment) were compared by Student's two-tailed t-test. 
2.4 RESULTS 
Synthesis of Metabolites. Etoposide was converted to its ortho-quinone and catechol in 
good yields (Figure 2.1) using the published methods of periodate oxidative demethylation and 
subsequent borohydride reduction (Pang S, et al., 2001). When the ortho-quinone was mixed 
with GSH in aqueous medium, the conjugate addition product (adduct) formed directly and in 
high yield without need for a transferase enzyme (Figure 2.1). These standard compounds were 
characterized spectroscopically, and their HPLC retention characteristics were examined. 
Analysis of the synthesized GSH adduct by MALDI-TOF-MS showed the m/z of the all-12C form 
of the protonated GSH adduct [M+H]+ to be 880.2373, 8 ppm from the calculated exact mass of 
the structure shown in Figure 2.1. The structure was further confirmed by using MALDI-
TOF/TOF-MS/MS analysis (Figure 2.2). Structures of the fragment ions were reasonably 
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assigned. For example, the fragment ion at m/z 754.2 confirmed the presence of the glutamate 
moiety, and the fragment ion at m/z 677.1 confirmed the sugar moiety on the etoposide portion of 
the structure. 
 
Figure 2.1 Synthesis of etoposide metabolites. 
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 Figure 2.2 MALDI-TOF/TOF-MS/MS fragmentation spectrum of the [M+H]+ ion (m/z 880) of 
synthetic etoposide ortho-quinone-glutathione adduct. 
 
Determination of the Etoposide ortho-Quinone-GSH Adduct in HL60 Cells Using 
LC-MS/MS. HL60 cells were found to produce the GSH adduct of etoposide ortho-quinone. 
The adduct was detected by nanoelectrospray LC-ion trap-MS and -MS/MS. As shown in Figure 
2.3, extracts of HL60 cells treated with 25 µM etoposide and 100 µM H2O2 showed a peak with 
a retention time of 16.4 min as detected at m/z 880.3, consistent with the [M+H]+ ion of the 
etoposide ortho-quinone GSH adduct and with the synthetic material. At the same time, another 
known etoposide metabolite, its catechol, was also detected in these extracts of the HL60 cells at 
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a retention time of 17.7 min. The [M+H]+ ion of the catechol was at m/z 575.2, which, along with 
the retention time, was consistent with the synthetic material. The structure of the GSH conjugate 
was confirmed by ion trap MS/MS by exciting the m/z 880.3 ion (Figure 2.4). The product ion 
spectrum showed production of diagnostic ions common to previously reported GSH adducts, 
including an abundant y2 ion at m/z 750.9 and a moderately abundant b2 ion at m/z 804.95 as 
expected for the structure depicted in Figure 2.4. Although the most abundant product ions were 
due to fragmentation within the GSH moiety, some product ions yielded information regarding 
the linkage between etoposide ortho-quinone and GSH. For example, the product ion at m/z 
544.95 corresponds to [M+H–Glu–206]+ and the fragment ion at m/z 674.0 corresponds to 
[M+H–206]+. The results were similar to the product ions of the synthetic GSH adduct observed 
by using MALDI-TOF-TOF (Figure 2.2). The product ion of m/z 604.98 was derived from the 
cleavage of the thioether moiety. Loss of water produced the fragment ions of m/z 862.23 
[M+H–H2O]+, m/z 733.87 [M+H–Glu–H2O]+, m/z 527.79 [M+H–Glu–206–H2O]+. The product 
ion of m/z 692.10 was the C2 ion derived from the product ion, which lost a glutamate moiety, 
and m/z 647.97 was the a2 ion derived from [M+H–Glu]+.  
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Figure 2.3 LC-ESI-ion trap MS analysis (positive ion, m/z 400-1800) of the etoposide ortho-
quinone-GSH adduct formed in HL60 cells when treated with etoposide and H2O2 at 37ºC for 
0.5h. (A) Extrated ion chromatogram showing the retention time of the adduct (m/z 880).(B) 
Extracted ion chromatogram showing the retention time of etoposide catechol (m/z 575). (c) 
Extracted ion chromatogram showing the retention time of etoposide (m/z 589). 
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Figure 2.4 LC-ESI-ion trap MS/MS fragment ion spectrum of the [M+H]+ precursor ion (m/z 
880) of the etoposide ortho-quinone-GSH adduct formed in HL60 cells. 
 
MPO Activity and Protein Levels. As shown in Figure 2.5, the activity of MPO 
significantly decreased when HL60 cells were pretreated for 68 h with the heme synthesis 
inhibitor succinylacetone (Nonaka T, et al., 1992). As expected, succinylacetone did not prevent 
production of the pre/pro forms of MPO in the HL60 cells but rather that of mature, heme-
containing MPO protein (Figure 2.6). Human leukemia K562 cells, which do not produce mature 
MPO protein, were used as a comparative negative blotting control.  
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 Figure 2.1 Significant difference in the myeloperoxidase (MPO) activity in HL60 cells without 
(SA–) or with (SA+) (P<0.05, N=7). 
 
 
 
Figure 2.2 Western blot analysis of myeloperoxidase (MPO) protein levels in HL60 cells 
without (–SA) or with (+SA). 
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MPO and Etoposide Dependency in the Production of the GSH Conjugate. HL60 
cells, with and without the 68 h pretreatment with succinylacetone to reduce the MPO level, 
were incubated with a range of etoposide concentrations. For quantification of the GSH adduct, 
we used a single quadrupole LC-MS system, the stable isotope-labeled form of the adduct as an 
internal standard, and selected ion monitoring. As can be seen in the chromatograms shown in 
Figure 2.7, no adduct formed in the absence of etoposide. When the HL60 cells were treated with 
25 µM etoposide, a small peak appeared at 7.0 min. The m/z signal and retention time of this 
analyte correlated exactly with that of the synthetic GSH adduct of etoposide ortho-quinone. The 
synthetic, stable isotope-labeled [13C215N-Gly] form of the adduct (200 pmol/sample) was added 
after the cell lysis step as an internal standard for isotope dilution quantitative studies. The 
amount of etoposide ortho-quinone-GSH conjugate from cells treated with 25 µM etoposide was 
dramatically increased by adding 100 µM H2O2, an MPO cosubstrate. This increase indicated 
that the endogenous concentration of H2O2 in the cells was low (likely because of catalase) and it 
was necessary to add more H2O2 to increase the rate and extent of the reaction. As shown in 
Figure 2.8, the GSH adduct formed in HL60 cells with succinylacetone pretreatment (for 25 µM 
treatment, n = 8) was significantly decreased as compared with the group without 
succinylacetone pretreatment (p < 0.001). These results indicated that the generation of the 
etoposide ortho-quinone conjugate with GSH depended on the level of mature and catalytically 
active MPO in HL60 cells.  
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Figure 2.7 Total ion chromatograms from LC-ESI-quadrupole MS analyses of methanolic 
extracts of HL60 cells treated with etoposide and/or H2O2 at 37ºC for 0.5h. (A) Control HL60 
cells (no etoposide, no H2O2). (B) HL60 cells treated with 25µM etoposide (no H2O2)-note the 
formation of the quinine-glutathione adduct at a retention time of 7min. (C) HL60 cells treated 
with 25µM etoposide and 100µM H2O2–note the markedly increased level of the adduct at 7 
min. 
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Figure 2.8 The formation of etoposide ortho-quinone-glutathione adduct in HL60 cells 
pretreated with (open squares) or without (closed diamonds) succinylacetone (SA) (P<0.001; for 
the 25µM treatment, N=8; for other concentration, N=3). 
 
Also shown in Figure 2.8 are the concentration dependency profiles of the GSH adduct 
formation for the two groups (with and without succinylacetone pretreatment). Succinylacetone 
pretreatment blocked ortho-quinone formation at all concentrations of etoposide studied by 90% 
or more. This result confirmed the conclusion that the formation of the GSH adduct depends on 
the level of MPO in intact HL60 cells. 
2.5 DISCUSSION 
The results presented here demonstrate that etoposide undergoes MPO-catalyzed 
metabolic activation in HL60 cells to form etoposide ortho-quinone, which binds to GSH 
covalently. MPO-rich HL60 cells were utilized as a convenient cellular surrogate for the myeloid 
progenitor CD34+ cell population that expresses MPO (Strobl H ,et al., 1993) and is the likely 
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origin for the myeloid leukemias induced by etoposide (Libura J, et al., 2005). We hypothesize 
that the genotoxic and carcinogenic effects of etoposide occur in myeloid progenitor CD34+ 
cells due to MPO-catalyzed oxidation of etoposide to its ortho-quinone. Hence, etoposide may 
cause myeloid but not other leukemia types because its quinone, formed due to MPO, induces 
greater Topo II-mediated DNA cleavage and therefore recombination events than does 
unmetabolized etoposide (Felix CA, 1998; Felix CA, 2001; Gantchev TG, et al., 1998; Lovett 
BD, et al., 2001).  
The etoposide ortho-quinone GSH adduct formed in HL60 cells was isolated, and its 
structure was verified by comparison of its mass spectral and chromatographic properties to 
those of synthetically prepared material. The level of the GSH adduct in HL60 cells, and by 
direct inference the MPO-mediated formation of the quinone, was substantially blocked by 
decreasing the levels of mature MPO after pretreatment with the heme synthesis inhibitor 
succinylacetone. MPO-catalyzed production of this etoposide metabolite was further established 
because addition of hydrogen peroxide, the necessary cosubstrate for MPO activity, bolstered 
production of the ortho-quinone. Finally, MPO appears to be the primary determinant of 
etoposide oxidative metabolism because the cytochromes P450 known to cause etoposide 
oxidations are not expressed appreciably in the undifferentiated HL60 cells used in this present 
work (Yu LJ, et al., 2001) nor in myeloid CD34+ precursors (Soucék P, et al., 2005). GSH, the 
most abundant intracellular nonprotein thiol, can react nonenzymatically and/or via catalytic 
assistance of gluthione S-transferase with electrophiles and free radicals. Etoposide ortho-
quinone was found to react nonenzymatically with GSH in vitro to give the conjugate addition 
product. It is unknown at present if glutathione-S-transferase catalyzes this reaction in HL60 
cells. Previous in vitro work (Gantchev TG, et al., 1998) demonstrates that GSH prevents 
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trapping of Topo II/DNA cleavable complexes by etoposide ortho-quinone, suggesting (to those 
authors) that the covalent adduct of etoposide ortho-quinone with GSH is inactive. It is not 
known, however, if the etoposide ortho-quinone-GSH adduct can act as a Topo II poison in a 
cellular context, which will be the subject of future studies.  
Previous work has shown that etoposide undergoes 1-e- oxidation to form its phenoxyl 
radical, which can be reduced by GSH (Kagan VE, et al., 1999). In the present study, we provide 
conclusive evidence that etoposide ortho-quinone, a 2-e- oxidation product, is generated by MPO 
in intact, undifferentiated HL60 cells through detection of its conjugate with GSH. It is unclear at 
present if the quinone is formed by two MPO-mediated 1-e- oxidation steps or by 
disproportionation of the 1-e- oxidation product, etoposide-O . Etoposide ortho-quinone has 
been suggested to be responsible in part for the cyto- and genotoxic effects of etoposide due to 
its ability to poison Topo II and stabilize Topo II/DNA covalent complexes in vitro (Gantchev 
TG, et al., 1998; Lovett BD, et al., 2001). As a quinone, it could conceivably also participate in 
redox cycling to generate reactive oxygen species, leading to an increase in oxidative DNA 
damage and an enhancement of recombination events linked to Topo II poisoning (Kingma PS, 
et al., 1997).  
Results from the present work indicate that a concentration of etoposide as low as 25 M 
is sufficient to trigger MPO-catalyzed oxidation to the ortho-quinone and yield detectable levels 
of its GSH adduct. This concentration of etoposide is well within the range attainable in plasma 
during commonly used regimens of chemotherapy and much below the plasma concentration of 
etoposide during a high-dose etoposide chemotherapy regimen (Nguyen L, et al., 1998; Rick O, 
et al., 1998).  
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Our results indicate that in the presence of exogenously added H2O2 the adduct 
concentrates in HL60 cells. Incubations with HL60 cells (1 × 106 cells/mL) were performed 
using etoposide (25-200 µM) in a final volume of 1 mL (25-200 nmol/1 × 106 cells). Under these 
conditions, conversion of 25 M etoposide to the GSH adduct ranged from ~0.11-0.18 nmol/1 × 
106 cells, a maximal conversion of 0.4%. Although this represents a small conversion of total 
drug, our results indicate that the etoposide ortho-quinone-GSH adduct concentrated within cells. 
For example, at 25 µM extracellular etoposide, the intracellular etoposide ortho-quinone-GSH 
adduct concentration was found to be 170 µM. At higher etoposide concentrations, there was an 
increase in GSH adduct formation that plateaued at a concentration of 275 µM, suggesting 
saturation of MPO-catalyzed oxidative activation of etoposide and subsequent steady state 
formation of the ortho-quinone metabolite.  
Measurement of reduced GSH within HL60 cells using an established technique (Kagan 
VE, et al., 2001) yielded a level of 2.9 nmol/1 × 106 cells. Using the intracellular water content 
for HL60 cells of 0.6 µL/1 × 106 cells (Karasavvas N, et al., 2005), the GSH concentration was 
estimated to be 4.8 mM. Because the maximal consumption of GSH based on formation of the 
etoposide ortho-quinone-GSH adduct is ~275 µM, there is very little depletion of the overall 
intracellular antioxidant reserve within cells by GSH conjugation to etoposide metabolites. It is 
more likely that oxidative stress caused by MPO-catalyzed oxidative activation of etoposide 
(Kagan VE, et al, 2001) is related to redox cycling of etoposide-O  and/or to cycling by 
etoposide ortho-quinone itself rather than by adduct-induced GSH depletion.  
In conclusion, the data presented demonstrate that etoposide ortho-quinone generated by 
MPO-catalyzed oxidation of etoposide can be captured by GSH in intact HL60 cells to give a 
mass spectrometrically detectable and quantifiable adduct. The ability to detect, characterize, and 
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quantify the GSH adduct in intact HL60 cells is important for future investigations of the 
mechanism(s) of etoposide-associated secondary leukemias and for estimating the risk of 
treatment-related secondary leukemias. Using myeloid progenitor CD34+ cells, future studies 
will be directed toward a better understanding of the role of etoposide metabolites in the myeloid 
leukemogenic process frequently associated with the clinical use of this antineoplastic agent. 
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3.0  METABOLISM OF (+)-DISCODERMOLIDE IN POOLED HUMAN LIVER 
MICROSOMES 
3.1 INTRODUCTION 
(+)-Discodermolide (Figure 3.1) is a natural product originally isolated from a marine 
sponge, Discodermia dissoluta (Gunaskekera et al., 1990).  
 
O
OH
OH
O OH
NH2
O
HO
O
7 11
17 19
24
1
3
5
15
13
 
Figure 3.1 The chemical structure of (+)-discodermolide. 
 
 
It was first introduced as an immunosuppressive agent (Longley et al., 1993), but then its 
mechanism of action was found to actually be potent microtubule stabilization (ter Haar et al., 
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1996; Kowalski et al., 1997). Unlike paclitaxel, a microtubule-stabilizing anticancer drug on the 
market, discodermolide is not a substrate for the P-glycoprotein efflux pump (Kowalski et al., 
1997). Discodermolide retains its antiproliferative potency againts β-tubulin mutant cells, unlike 
the epothilones (He et al., 2001). Although they compete for binding to microtubules, when 
discodermolide and paclitaxel are combined, there is a significant increase in antiproliferative 
activity against both cell lines and xenografts in mice (Huang et al., 2006). The potency and 
novel structure of (+)-discodermolide make it a promising candidate for clinical development as 
an anticancer drug. 
Over the late 1990’s and early 2000’s, Novartis Corp. developed discodermolide to the 
stage of Phase II clinical trials in humans. Abruptly in late 2004, the company announced the 
withdrawal of the agent from development, without explanation (Novartis, 2004). It is suspected 
that undue toxicities were noted during dose escalation, but no official or scientific report has 
emerged to explain this action. Interestingly, only some scant pharmacokinetic data and no 
metabolic studies of discodermolide have been reported (Mani, et al., 2004). The numerous 
allylic positions, pendant methyl groups and double bonds in the molecule led to the hypothesis 
that the compound is extensively metabolized by cytochromes P450, The present studies were 
then undertaken to address this hypothesis, to provide information on the metabolic stability of 
discodermolide and to begin to determine structures of metabolites from human liver 
microsomes. 
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3.2 MATERIALS AND METHODS 
Chemicals. Discodermolide was synthesized by Novartis Corp. and provided as a gift by 
Drs. Kenneth Bair and Fred Kinder. HPLC grade acetonitrile and water were purchased from 
Burdick & Jackson (Muskegon, MI). All other chemicals were purchased from Sigma-Aldrich 
(St.Louis, MO). 
 
Human Liver Microsomes. Pooled human liver microsomes were purchased from BD 
Gentest (Woburn, MA). The cytochrome P450 content was 0.33 nmol/mg of protein. 
 
Microsomal Incubations. A typical incubation mixture (0.5 mL) contained 0.1 mg/mL 
of microsomal protein, 10 µM discodermolide and 1 mM NADPH in 100 mM phosphate buffer, 
pH 7.4. The incubation was carried out for 15 min at 37 ºC and stopped by addition of 0.5 mL of 
cold acetonitrile to precipitate proteins. Samples were centrifuged and the supernatant was 
evaporated on a SpeedVac. Controls were the incubation without NADPH. (+)-Discodermolide 
was incubated at a concentration of 10 µM with pooled human liver microsomes for 0, 15, 30 
and 60 min to determine the time period that gave rise to the maximum number of metabolites. 
Although some increase in metabolite concentrations was observed at the latter two time points, 
the 15 min incubation time gave rise to the same number of metabolites in the same relative 
abundances and was therefore chosen for detailed analyses. 
 
LC-MS Analysis. Reverse phase HPLC separations were carried out using a prepacked 
Pico Frit C18 column. The mobile phase consisted of 0.1% formic acid in water (solvent A) and 
0.1% formic acid in acetonitrile (solvent B). The elution program was as follows: isocratic at 
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23% B for 5 min, linear gradient from 23% to 70% B over 10 min, isocratic at 70% B for 10 min, 
linear gradient from 70% to 95% B over 1 min, isocratic at 95% B for 4 min. The flow rate was 
160 nL/min. The column effluent was fed into a Thermo Finnigan LCQ Deca XP Plus mass 
spectrometer equipped with a nanoelectrospray source. Spray voltage was set at 1.43 kV, 
capillary temperature at 180 ºC and capillary voltage at 40 V. The normalized collision energy 
used was 35%. Accurate mass analyses were performed on an ABI QSTAR Elite Qq-TOF 
system equipped with a Nanospray II source. The ionspray voltage was 2.5 kV and the ion 
source temperature was 120 ºC. The Qq-TOF was tuned to 13,000 resolution at half maximum. 
Reserpine ([M+H]+ at m/z 609.2812) was used as the autocalibration mass. The obtained mass 
accuracy of metabolites was + 10 ppm. 
3.3 RESULTS 
Identification of Metabolites.  At least eight metabolites of discodermolide were 
detected by LC-MS analysis after incubation of the compound with pooled human liver 
microsomes. The chromatogram of metabolites and discodermolide is shown in Figure 3.2A. The 
chromatogram of control sample is shown in Figure 3.2B.  
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Figure 3.1 (A) Positive ion LC-MS/MS total ion chromatogram and extracted ion 
chromatograms of 10 µM (+)-discodermolide and its metabolites after incubation with pooled 
human liver microsomes for 15min with NADPH. (B) The total ion chromatogram of the control 
incubation (without NADPH). 
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The metabolites were characterized by comparing their product ion spectra to that of the 
corresponding parent drug. Typical fragmentation patterns of discodermolide showed cleavage at 
i) the C-C bond adjacent to the C11-hydroxyl group (C10-C11) to give the fragments at m/z 352, 
m/z 334 (–H2O) and m/z 225 (–H2O), and ii) the C-C bond adjacent to the 17-hydroxyl group 
(C17-C18) to give the fragments at m/z 411 and 393 (–H2O) (Table 3.1 and Figure 3.3A). The 
ion of m/z 393 fragmented further in MS3 spectrum (Fig. 3.3B) by cleavage of C-C bond near 7-
hydroxyl group (C7-C8) to form the m/z 171 ion. The lactone ring of the ion of m/z 393 was 
fragmented in MS3 experiments by cleavage of C1-O bond and C4-C5 bond to form the m/z 279 
ion, and/or by cleavage of C1-O bond and C3-C4 bond following by loss of water to form the 
m/z 291 ion. These two fragments in the MS3 experiments proved important in the identification 
of the structures of metabolites. The proposed fragmentation pattern is shown in Figure 3.4. 
 
Table 3.1 Results of LC-MS/MS analysis of the metabolites of (+)-discodermolide. 
Metabolite m/z Major Fragment Ions in MS2 Spectra, m/z 
Discodermolide 594 393, 334 
M1 628 610, 592, 567, 549, 531, 513, 411, 393, 385, 368, 225 
M2 628 610, 592, 567, 549, 531, 513, 411, 393, 385, 368, 225 
M3 610 592, 574, 549, 409, 391, 368, 350, 337, 307,289, 271, 225 
M4 610 592, 574, 549, 531, 513, 409, 391, 350, 337, 322 ,289, 261 
M5 610 592, 574, 549, 531, 513, 495, 409, 391, 350, 337, 307,289 
M6 610 592, 574, 549, 531, 513, 495, 393, 350, 337, 307,289 
M7 610 592, 574, 549, 531, 513, 409, 350, 307,289 
M8 592 391, 334 
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Figure 3.2 Ion trap MS2 (A) and MS3 (m/z 594→m/z 393) (B) product ion spectra of 
discodermolide. 
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Figure 3.3 Tandem mass spectrometry fragmentation pathways of the [M+H]+ ion of 
discodermolide. 
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  Metabolite M8. Metabolite M8 produced a protonated molecular ion at m/z 592.3848, 
which corresponded to a net loss of two hydrogen atoms from discodermolide. This 
biotransformation may be the direct dehydrogenation or the monooxidation followed by a loss of 
water molecule. In addition, the retention time of M8 was longer than that of the parent 
compound, indicating that M8 was of lower polarity. The MS2 product ion spectrum of M8 
contained abundant ions of m/z 391 and m/z 334 (Figure 3.5A), which suggested that the right 
(carbamate-containing) side and middle portion of the molecule were unchanged, and that 
dehydrogenation took place on the left (delta lactone-containing) side. In contrast to parent drug, 
the cleavage of the C1-O bond and C4-C5 bond was not observed in the MS3 spectrum of the m/z 
391 ion (Figure 3.5B), but cleavage of C1-O and C3-C4 were detected. The cleavage of C1-O 
and C3-C4 followed by a loss of water formed the ion at m/z 271 in this MS3 spectrum, 
indicating that the dehydrogenation might have occurred at C4-C5. Loss of two water molecules 
was relatively facile from the m/z 391 ion (in the related MS3 spectrum of discodermolide, only 
one of the hydroxyl groups was eliminated through loss of water). This suggested the presence of 
double bond at C4-C5 so that loss of an additional water molecule from the 7-hydroxy group 
would form a conjugated system that would delocalize and stabilize the positive charge on the 
m/z 271 ion. Another important diagnostic fragment was recorded at m/z 169 with high 
abundance compared with the fragment at m/z 171 from discodermolide product ion at m/z 393 
in MS3 spectrum. It is proposed that the m/z 169 ion originated from homolytic cleavage of the 
C7-C8 bond followed by loss of water and stabilization by the resulting conjugated system 
(Figure 3.6). Based on these considerations, M8 was assigned as C4-C5 dehydrodiscodermolide. 
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Figure 3.4 Ion trap MS2 (A) and MS3 (m/z 592→m/z 391) (B) product ion spectra of metabolite 
8 (M8). 
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Figure 3.5 Tandem mass spectrometry fragmentation pathways of the [M+H]+ ion of M8. 
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Metabolite M1. Metabolite M1 yielded an [M+H]+ ion at m/z 628. The observed 
accurate mass for M1 was m/z 628.4010, which corresponded to a product of monooxygenation 
plus hydrolysis with an elemental composition of C33H57NO10. M1 yielded fragmentation 
patterns similar to those of the parent compound , The fragmentogram is shown in Figure 3.7A. 
The cleavage occurred at the C10-C11 and C17-C18 bonds. These fragment ions were detected 
at m/z 368 and m/z 393, which suggested that oxidation took place on the right side of the 
molecule instead of left side and in the middle (proposed fragmentation patterns are shown in 
Figure 3.8). Metabolite M1 also yielded a fragment ion at m/z 549, which correspond to the loss 
of two H2O and one CONH (549 = 628–36–43) (Figure 3.7A and Table 3.1). Further 
fragmentation of the ion at m/z 549 of M1 in an MS3 spectrum gave the most informative 
fragment ion at m/z 485. This ion corresponded to a loss of CO and two water molecules (485 = 
549–36–28) (Figure 3.7B). This indication of the presence of a CO group strongly suggested that 
oxidation occurred on the terminal double bond of the right side (C23-C24) to form 23,24-
dihydroxydiscodermolide, the structure assigned to M1.  
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Figure 3.6 Ion trap MS2 (A) and MS3 (m/z 628→m/z 549) (B) product ion spectra of metabolite 
1 (M1). 
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Figure 3.7 Tandem mass spectrometry fragmentation pathways of the [M+H]+ ion of M1. 
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Metabolite M2. Metabolite M2 also yielded an [M+H]+ ion at m/z 628. The observed 
accurate mass for M2 was m/z 628.3999, also corresponding to a product of monooxygenation 
plus hydrolysis with an elemental composition of C33H57NO10. M2 yielded fragmentation 
patterns similar to the parent compound (Figure 3.9A and Table 3.1). In the MS/MS spectrum, 
cleavage was, like M1, at the C10-C11 and C17-C18 bonds to give ions at m/z 368 and m/z 393, 
again suggesting that oxidation took place on the right side of the molecule (proposed 
fragmentation patterns are shown in Figure 3.10). M2 also showed the fragment ion at m/z 549 
(loss of two H2O and one CONH) (Figure 3.9A and Table 3.1). However, the MS3 spectrum 
(Figure 9B) of the ion at m/z 549 did not show the same diagnostic ion as seen in M1. Therefore, 
most possible dihydroxylation positions for M2 were deemed to be at C21 and C22 (Figure 
3.10).  
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Figure 3.8 Ion trap MS2 (A) and MS3 (m/z 628→m/z 549) (B) product ion spectra of metabolite 
2 (M2). 
 
MS3_628 #434 RT: 7.34 AV: 1 NL: 3.08E5
F: + c NSI Full ms3 628.00@35.00 549.00@30.00 [ 150.00-650.00]
360 380 400 420 440 460 480 500 520 540
m/z
0
10
20
30
40
50
60
70
80
90
100
R
el
at
iv
e 
A
bu
nd
an
ce
531.02
513.14
495.07
433.06
429.34
531.90495.78
B 
200 250 300 350 400 450 500 550 600 650 700
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
el
at
iv
e 
A
bu
nd
an
ce
610.15
592.08368.08
531.07
549.02
513.32385.58
567.06
307.07
393.19
338.97 495.23 611.22409.20 446.72224.97 350.29 477.53288.95 337.03214.98 271.20
A 
 66 
OOH
OH
O OH O
NH2
O
HO
m/z 368
O
OH
O
HO
m/z 549
OH
m/z 628
H+
H+
-H2O
m/z 513
-2H2OMS3
OH O
NH2
O
OH
-H2O
O
OH
HO
m/z 433
OH
OO
HO
H+
OH
MS3
OH
OH
OH
OH
+
+
O
O
O
 
Figure 3.9 Tandem mass spectrometry fragmentation pathways of the [M+H]+ ion of M2. 
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Metabolite M3. Metabolite M3 eluted after the dihydroxylation products. This 
metabolite showed a protonated molecular ion at m/z 610. The observed accurate mass of M3 
was at m/z 610.3917, corresponding to a monooxygenation product with an elemental 
composition of C33H55NO9. 
M3 yielded MS/MS fragment ions of m/z 391 and m/z 350 (Figure 3.11A and Table 3.1), 
indicating that oxidation occurred in the middle portion of discodermolide (Figure 3.12). The 
most informative fragment ions in the MS3 spectrum of m/z 350 were detected at m/z 320, 241 
and 161 (Figure 3.11B). These corresponded to a loss of formaldehyde (HCHO) from the m/z 
350, 271 and 191 ions (Figure 3.12). The ion at m/z 271 was produced by loss of one CONH 
group and two water molecules from the m/z 350 ion. The ion at m/z 191 was produced by the 
cleavage of C19-C20 bond followed by loss of one CONH group and two water molecules. This 
loss indicated the presence of a CH2OH group and strongly suggested that oxidation occurred on 
the terminal methyl groups near C13-C14 to produce 14-(1’-hydroxy)discodermolide (see Figure 
3.12).  
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Figure 3.10 Ion trap MS2 (A) and MS3 (m/z 610→m/z 350) (B) product ion spectra of M3. 
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Figure 3.11 Tandem mass spectrometry fragmentation pathways of the [M+H]+ ion of M3. 
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Metabolite M4. M4 eluted after M3. This metabolite gave an [M+H]+ ion at m/z 610 and 
an accurate mass of m/z 610.3926, corresponding to a monooxygenation product with an 
elemental composition of C33H55NO9. 
The abundant M4 fragment ions of m/z 391 and 350 indicated that oxidation occurred in 
the middle portion of discodermolide. The product ion mass spectrum of M4 also showed 
unusual fragments at m/z 322 and 261. The most probable structure for M4 is 12-
hydroxydiscodermolide. Based on this structure, the fragment ion at m/z 322 can be explained to 
arise by homolytic cleavage of the C11-C12 bond, initiated by a positive charge located on the 
C12 hydroxyl group. The fragment ion at m/z 261 would therefore have arisen from additional 
loss of the CONH group and a water molecule (Figure 3.14).  
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Figure 3.12 Ion trap MS2 product ion spectra of M4. 
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Figure 3.13 Tandem mass spectrometry fragmentation pathways of the [M+H]+ ion of M4. 
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Metabolite M5. Metabolite M5 eluted after M4, also gave an [M+H]+ ion at m/z 610, and 
an accurate mass determination of m/z 610.3912, which corresponded to a monooxygenation 
product with an elemental composition of C33H55NO9. 
The product ion spectrum of M5 was dominated by the fragment ions at m/z 391 and 350 
(Figure 3.15A and Table 3.1), and suggesting that oxidation occurred in the middle portion of 
discodermolide. A unique fragment ion at m/z 322 was detected in MS3 spectrum of the ion at 
m/z 350 (Figure 3.15B), corresponding to the loss of a CO moiety. This implied the presence of a 
formaldehyde group on the m/z 350 ion. Another interesting feature in the MS3 spectrum of m/z 
350 was the ion at m/z 259, which corresponded to the loss of one CONH group, one water 
molecule and formaldehyde (HCHO). This loss indicated the presence of a CH2OH group and 
suggested the metabolic oxidation occurred on a terminal methyl group. Since the C14 methyl is 
the only methyl group near the double bond in the middle portion, and oxidation at this position 
was already assigned to M3, it is therfore highly possible that M5 was oxygenated on the C12 
methyl group. The double bond between C13 and C14 might have migrated to C12-C13. Based 
on this structure, the fragment ion at m/z 322 can be explained by the loss of a CO moiety from 
the formaldehyde group on the ion at m/z 350 (see the structure in Figure 3.16). The reason of 
formation of a formaldehyde group on the ion at m/z 350 after the cleavage of C10-C11 bond 
would be due to the lack of a hydrogen on C12, and therefore the loss of water after cleavage of 
C10-C11 could not occur. 
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Figure 3.14 Ion trap MS2 (A) and MS3 (m/z 610→m/z 350) (B) product ion spectra of M5. 
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Figure 3.15 Tandem mass spectrometry fragmentation pathways of the [M+H]+ ion of M5. 
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Metabolite M6. Metabolite M6 eluted after M5. Like M3-M5, its [M+H]+ appeared at 
m/z 610. The accurate mass determination of M6 gave m/z 610.3919, again corresponding to a 
monooxygenation product with an elemental composition of C33H55NO9.  
The MS/MS spectrum of M6 showed fragment ions at m/z 393 and 350 (Figure 3.17A 
and Table 3.1), suggesting that oxidation took place in the right side of discodermolide. Further 
fragmentation of the ion at m/z 350 (Figure 3.17B) gave the most informative fragment ion at m/z 
320, which indicated a loss of formaldehyde from m/z 350. The loss of HCHO strongly 
suggested that metabolic oxidation occurred on the only terminal methyl group in the right side 
of discodermolide, the methyl at C21. The most likely structure consistent with the formation of 
the ion at m/z 320 includes migration of the double bond of the right side (Figure 3.18). This 
double bond migration would also generate another terminal methyl group at C24. Therefore, the 
possibility that the hydroxyl group was added on the terminal methyl group on C24 after double 
bond migration cannot be excluded. 
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Figure 3.16 Ion trap MS2 (A) and MS3 (m/z 610→m/z 350) (B) product ion spectra of M6. 
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Figure 3.17 Tandem mass spectrometry fragmentation pathways of the [M+H]+ ion of M6. 
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Metabolite M7. The metabolite M7 eluted after M6 but before the parent compound and 
M8. Like M3-M6, its protonated molecular ion appeared at m/z 610 and the accurate mass 
determination yielded m/z 610.3922. This was another monooxygenation metabolite with the 
composition C33H55NO9. 
The MS2 spectrum of M7 showed fragment ions at m/z 391 and m/z 350 (Figure 3.19A 
and Table 3.1), indicating that oxygenation occurred in the middle portion of discodermolide. At 
this point, all the highly possible sites for monooxygenation in the middle portion, except C15, 
had been assigned. Further fragmentation of the ion at m/z 350 (Figure 3.19B) produced an 
interesting ion at m/z 272. The even nature of this ion implied the presence of an odd number of 
nitrogen atoms, i.e., one. The fragment ion at m/z 272 was thus likely generated by the cleavage 
of the C14-C15 bond near the metabolically added hydroxyl group. Therefore, the most probable 
structure of M7 is 15-hydroxydiscodermolide (Figure 3.20). 
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Figure 3.18 Ion trap MS2 (A) and MS3 (m/z 610→m/z 350) (B) product ion spectra of M7. 
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Figure 3.19 Tandem mass spectrometry fragmentation pathways of the [M+H]+ ion of M7. 
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3.4 DISCUSSION 
Although discodermolide has been under development as an anticancer drug for many 
years, nothing has been reported regarding its metabolism. Discodermolide was selected for 
study here due to some features that will have an impact on clinical development, such as 
potential toxicity and its reported rapid clearance rate from plasma in a preliminary ADME study 
(Mita C, et al., 2003). The present experiments showed that discodermolide is susceptible to 
biotransformation in vitro by human liver microsomes, and the appearance of multiple 
metabolites resulting from monoxygenation supported the hypothesis that the compound is 
metabolized by cytochromes P450. The data show the metabolic soft spots in the molecule, 
which may be responsible for its high clearance. Furthermore, the numerous metabolites might 
be a source of toxicity.   
The LC-MS/MS results yielded useful information about the fragmentation patterns of 
the metabolites and the parent drug, particularly the ions at m/z 350 and 393. However these ions 
alone were not enough to identify the structures of metabolites. MS3 spectra were therefore 
generated in a 3D ion trap as an additional tool to identify the structures of metabolites. 
Human liver microsomes converted discodermolide into at least eight metabolites 
(summarized in Figure 3.21).  
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Figure 3.20 Proposed biotransformation pathways of (+)-discodermolide by pooled human liver 
microsomes. 
 
These metabolites were either dehydrogenation or oxygenation products of 
discodermolide. The epoxidation of the diene moiety in the right side of discodermolide was 
followed by hydrolysis of the oxirane to give metabolites M1 and M2. The predominance of this 
metabolic pathway is not surprising given steric consideration for the attack to this site. Because 
of the Z-double bonds and substituent pattern particularly in the middle portion of the molecule, 
discodermolide is known to adopt a ‘tilde’ or ‘corkscrew’ shape, both in solution and in the 
crystal form (Sanchez-Pedregal VM et al., 2006). This leaves the diene group of discodermolide 
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as the most exposed and thus accessible to the attack by CYP450 enzymes. This finding might be 
significant in terms of compound optimization, since the terminal diene system does not 
contribute significantly to the biological activity of discodermolide (Smith et al., 2005). 
Substitution of terminal diene group with saturated carbon systems would increase metabolic 
stability of the compound without sacrificing the biological activity. Previous SAR studies have 
showed that an analogue of discodermolide with an unsaturated latone ring has slightly higher 
potency than parent drug (Smith et al., 2005). Here it was found that discodermolide could be 
dehydrogenated at C4-C5 to form metabolite M8. Based on the chemical structures of M1, M2 
and M8, It is  proposed that an analogue of discodermolide, which may have higher metabolic 
stability, should be prepared. The structure of this molecule is shown in Figure 3.22. 
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Figure 3.21 Structure of an analogue of discodermolide proposed for synthesis based on 
the metabolism of the parent drug.. 
 
 
Another interesting observation was the detection of double bond migration of C13-C14 
and C21-C22 in metabolites M5 and M6. These migrations might be caused by the delocalization 
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of the unpaired electrons of radicals generated by CYP450 enzyme onto the other carbons of the 
allylic system. 
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4.0  METABOLISM OF (–)-DICTYOSTATIN IN POOLED HUMAN LIVER 
MICROSOMES 
4.1 INTRODUCTION 
As outlined in the previous chapter, the microtubule system is an important target for 
cancer therapy as evidenced by the clinical success of the taxanes, so the search continues for 
agents that cause microtubule stabilization. (–)-Dictyostatin is a unique 22-membered 
macrocyclic lactone (Figure 4.1).  
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Figure 4.1 The chemical structure of (−)-dictyostatin 
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It was first isolated from a Republic of Maldives marine sponge in the genus Spongia in 
extremely low yield (3.4 x 10-7%) in 1994 and was found to strongly inhibit the cell growth of 
murine P388 lymphocytic leukemia cells (Pettit GR, et al., 1994). In 2003, dictyostatin was 
identified as a highly active microtubule stabilizing agent in an extract from a Lithistida sponge 
of the family Corallistidae collected off the north cost of Jamaica. Dictyostatin was found to 
arrest cells in the G2/M phase and to induce the polymerization of tubulin in vitro. Dictyostatin 
was also highly potent against two paclitaxel-resistant human cancer cell lines overexpressing P-
glycoprotein (Isbrucker RA, et al., 2003). This data makes dictyostatin a promising compound 
for further study.  
Because of the low availability from natural sources, the full evaluation of dictyostatin 
was difficult. The relative stereochemistry of dictyostatin was determined by high field NMR 
and molecular modeling in 2004 (Paterson I, et al., 2004). Total syntheses of (–)-dictyostatin 
were simultaneously reported by Paterson (Paterson I et al., 2004) and Curran (Shin Y, et al., 
2004), and later by Phillips (O’Neil GW, et al., 2006) and Ramachandran (Ramachandran PV, et 
al., 2007). These total syntheses allowed evaluation of dictyostatin’s therapeutic potential. 
Nothing is known about the metabolism of (–)-dictyostatin. Because of the extensive 
metabolism of the closely related compound (+)-discodermolide reported in the previous chapter, 
as well as the clinical failure of the agent, the in vitro biotransformation of synthetic (–)-
dictyostatin in pooled human liver microsomes was examined. The hypothesis was that 
dictyostatin would also be a substrate for cytochromes P450, but that its cyclic structure might 
limit, as compared to discodermolide, the number of metabolites formed. The metabolites of 
dictyostatin were identified using liquid chromatogram ion trap mass spectrometry and are 
reported here. 
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4.2 MATERIALS AND METHODS 
Chemicals. Dictyostatin was synthesized by Prof. Dennis Curran’s group at the 
University of Pittsburgh (Shin Y et al., 2004). All other chemicals were purchased from Sigma-
Aldrich (St.Louis, MO).  HPLC grade acetonitrile and water were purchased from Burdick & 
Jackson (Muskegon, MI).  
Human Liver Microsomes. Pooled human liver microsomes were purchased from BD 
Gentest (Wobum, MA). The cytochrome P450 content was 0.33 nmol/mg of protein. 
Microsomal Incubations. A typical incubation mixture (0.5mL) contained 0.2mg/mL of 
microsomal protein, 10 µM dictyostatin, and 100 mM phosphate buffer, pH7.4. The reaction was 
initiated by adding of NADPH regeneration system (BD Bioscience, San Jose, CA), which 
included 1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 0.4 U/mL glucose-6-phosphate 
dehydrogenase, and 3.3 mM magnesium chloride. The incubation was carried out for 15 min at 
37 ºC and was stopped by addition of 0.5 mL of cold acetonitrile to precipitate proteins. Control 
reactions contained all the components except microsomal protein or no NADP+ was added. 
HPLC. Reverse phase HPLC separations were carried out using a prepacked Pico Frit 
C18 column (7.5 µm x 10 cm, New Objectives, Inc.). The column was eluted with 0.1% formic 
acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B). The initial condition 
was 35% solvent B. The gradient as follows: isocratic 35% B for 5 min, linear gradient from 
35% to 70% B over 10 min, isocratic at 70% B for 5 min, linear gradient from 70% to 95% B 
over 1 min, then isocratic at 95% B for 4 min. The flow rate was 155 µL/min. The injection 
volume was 1 µL. 
LC-MS/MS Analysis. A Thermo Electron LCQ Deca XP Plus mass spectrometer with a 
nanospray source (Thermo Electron Corporation) was used for MS/MS analysis of dictyostatin 
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metabolites. Positive ions were monitored. Spray voltage was set at 1.43 kV, capillary 
temperature was 180 ºC and the capillary voltage was 40 V. Activation energy for fragmentation 
was set at 30%. 
4.3 RESULTS 
             Metabolite Identification.  Pooled human liver microsomes with a cytochrome P450 
content of 0.33 nmol/mg of protein were diluted to 0.2 mg/mL in 100 mM phosphate buffer 
containing 10 µM (–)-dictyostatin and reactions were initiated at 37 oC with a glucose-6-
phosphate dehydrogenase-based NADPH regenerating system. Final reaction volumes were 0.5 
mL. Reactions were allowed to proceed for 15 min and proteins were precipitated by addition of 
ice-cold acetonitrile 
The total ion chromatogram and the extracted ion chromatograms for the positive ion 
nanospray LC-MS/MS analysis of of 10 µM (–)-dictyostatin incubated with active pooled human 
liver microsomes is shown in Figure 4.2A. Control incubations without microsomal protein or 
without NADP(H) showed no degradation and oxygenation of the parent molecule (Figure 4.2B). 
Six major metabolites were detected, all as their protonated molecular ions. The corresponding 
product ion mass spectra obtained using the ion trap and the proposed fragmentation pathways 
for (–)-dictyostatin and its metabolites are listed in Table 4.1 and depicted in Figures 4.3-4.18. 
Detailed discussions of each are given below.  
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Figure 4.2 (A) Positive ion LC-MS total ion and extracted ion chromatograms of 10 µM (–)-
dictyostatin after incubation with pooled human liver microsomes at 37ºC for 15min with 
NADPH. (B) Total ion chromatogram of incubation without NADPH. 
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Table 4.1 Mass spectrometric data for (-)-dictyostatin and its metabolites. 
Metabolite [M+H]+ m/z Major Fragment Ions in MS2 Spectra 
Dictyostatin 533 453, 415, 393, 375, 357, 339, 329, 279, 261, 243 
M1 567 513, 483, 477, 471, 449, 433, 419, 375, 339, 295, 277 
M2 567 477, 471, 431, 421, 375, 339, 295, 277, 259 
M3 549 495, 465, 431, 413, 391, 355, 295, 277, 265 
M4 549 469, 413, 391, 373, 359, 331, 295, 277, 259, 241 
M5 549 451, 393, 375, 359, 295, 277, 265 
M6 549 469, 409, 391, 309, 291, 279 
 
 
Dictyostatin. The major fragmentation pathway for the parent molecule (–)-dictyostatin 
was the cleavage of the C1-O bond of the macrocyclic lactone ring, followed either by the 
cleavage of the C12-C13 bond near the C13-hydroxyl to give the fragment ion at m/z 279 or by 
the cleavage of C19-C20 bond near the C19-hydroxyl to give the fragment ion at m/z 393 (Figure 
4.3). As the reader will see later in this chapter, this pathway proved very useful for the 
determination of the sites of metabolic transformation on (–)-dictyostatin. The loss of water 
molecules from the m/z 393 fragment ion gave rise to the m/z 375, m/z 357, and m/z 339 ions. 
Likewise, the loss of the water molecules from the m/z 279 fragment ion gave rise to the m/z 261 
and m/z 243 ions. The loss of a CO moiety from the m/z 357 ion gave the m/z 329 ion. Other 
minor fragmentation pathways included the cleavage of the C21-C22 bond to give the m/z 453 
product ion, and the cleavage of the C8-C9 and C12-C13 bonds to give m/z 415 product ion. The 
proposed fragmentation pathways of (–)-dictyostatin are shown in Figure 4.4. 
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Figure 4.3 Positive ion nanospray MS/MS product ion mass spectrum of the protonated 
molecular ion of (–)-dictyostatin. 
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Figure 4.4 Tandem mass spectrometry MS/MS fragmentation pathways of the protonated 
molecular ion of (–)-dictyostatin. 
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Metabolite M1. Metabolite M1 was the first eluting peak during the reverse phase 
nanoflow LC separation. This relatively high polarity implied M1 to be the most hydrophilic 
metabolite. The [M+H]+ ion of M1 appeared at m/z 567, making the mass difference between the 
parent compound and M1 +34 Da, which corresponded to monooxidation (+16 Da) plus 
hydrolysis (+18 Da). The MS/MS spectrum of M1 is shown in Figure 4.5. Abundant fragment 
ions were detected at m/z 295 and m/z 375, the latter corresponding to the loss of water from the 
m/z 393 ion. The loss of two water molecules from m/z 375 gave the ion at m/z 339 and the loss 
of one water molecule from m/z 295 gave the ion at m/z 277. Recall that the ion at m/z 375 was 
also detected in the MS/MS spectra of (–)-dictyostatin. The 16 Da difference between the ion at 
m/z 295 in the MS2 spectrum of M1 and the m/z 279 ion in the MS2 spectrum of (-)-dictyostatin 
suggested that the oxidation took place somewhere between C19 and C26, and that the 
macrolactone ester bond had hydrolyzed (see the proposed fragmentation pathway in Figure 4.6). 
Elimination of three water molecules from the protonated molecular ion gave rise to m/z 513; 
subsequent neutral loss of 30 Da from this ion produced m/z 483, which corresponds to a 
formaldehyde moiety. Collectively, this fragmentation pattern suggested that M1 is dictyostatin 
hydroxylated on a terminal methyl group. In addition, neutral loss of 30 Da from m/z 449 to give 
m/z 419 was observed. The m/z 449 corresponds to the loss of five water molecules and a CO 
moiety from the protonated molecular ion of M1.  The ion at m/z 471 and m/z 433 were also 
observed in the MS/MS spectrum of M1, corresponding to the cleavage of the C21-C22 bond 
and the cleavage of C21-C22 followed by elimination of two water molecules and two hydrogen 
atoms, respectively. This suggested that the hydroxylation did not take place on the C19, C20 or 
C21 carbons. It is possible that M1 was generated by hydroxylation of the methyl group on C22 
followed by the hydrolysis of the lactone ring after double bond migration. Such a double bond 
 94 
migration would also generate another terminal methyl group on C25, so the possibility that the 
hydroxylation occurred at this position can not be excluded. Based on the results, the structure of 
M1 was assigned as the lactone hydrolyzed version of the parent molecule also hydroxylated at 
either the C22 methyl group or at the C25 after double bond migration.  
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Figure 4.5  MS2 spectrum of the protonated molecular ion (m/z 567) of metabolite M1. 
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Figure 4.6 MS/MS fragmentation pathways of the protonated molecular ion of M1. 
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Metabolite M2. M2 eluted after M1. The retention times of M1 and M2 were close to 
each other. The [M+H]+ ion of M2 was the same as that of M1, m/z 567 indicating that M2 was 
also a hydroxylated macrolactone hydrolysis product of (–)-dictyostatin. The mass spectral 
fragmentation pattern of M2 was very analogous to that of M1. Dissociation of the [M+H]+ at 
m/z 567 produced two major fragment ions at m/z 375 and m/z 295 (see Figure 4.7), suggesting 
that the oxidation took place between C19 and C26 and that the ester bond was hydrolyzed (see 
the proposed fragmentation pathway in Figure 4.8). The neutral loss of five water molecules 
from the protonated molecular ion of M2 produced the m/z 477 ion, and the subsequent loss of 
one water molecule and one CO moiety gave rise to the m/z 431 ion. The loss of water molecules 
from m/z 295 generated the m/z 277 and m/z 259 ions. The ion at m/z 471, also detected in the 
MS/MS spectrum of M1, was observed. This informative fragment ion narrowed down the 
possible hydroxylation site to the C22-C26 region. No ions corresponding to the loss of 
formaldehyde were observed in the MS/MS spectrum of M2, suggesting that the oxygenation did 
not occur on the terminal methyl group of (–)-dictyostatin. A moderately abundant signal at m/z 
421 was detected in the MS/MS spectrum of M2. This ion was unique in all MS/MS spectra of 
all metabolites of (–)-dictyostatin, plus was not observed in the MS/MS spectra from the parent 
molecule. It is highly possible that the hydroxyl group of M2 resides on C22. The cleavage of 
C22-C23 afforded the most important diagnostic ion at m/z 421. This assignment is supported by 
the relatively similar HPLC retention time of M2, which was only slightly less polar than the 
apparently closely related M1. 
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Figure 4.7 MS2 spectrum of the protonated molecular ion (m/z 567) of metabolite M2. 
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Figure 4.8 MS/MS fragmentation pathways of the protonated molecular ion of M2 
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 Metabolite M3. M3 eluted after M2 and gave rise to the [M+H]+ ion detected at m/z 549. 
The [M+H]+ ion for M3 was 16 Da higher than that of (–)-dictyostatin, indicating M3 to be a 
monooxygenation metabolite. The MS/MS spectrum of M3 is presented in Figure 4.9. The 
fragment ion at m/z 295 corresponded to the cleavage of the C1-O and C12-C13 bonds and loss 
of a water molecule (see Figure 10). Elimination of another water molecule gave rise to the ion at 
m/z 277. Compared to the MS/MS spectrum of the parent compound, the ion at m/z 295 was 16 
Da higher than (–)-dictyostatin’s m/z 279 ion, which was presumed to be produced by the same 
cleavage. This implied that the oxygenation took place between C19-C26. The cleavage of the 
C9-C10 and C12-C13 bonds gave rise to the product ion at m/z 431, and subsequent loss of H2O 
afforded the ion at m/z 413. The m/z 415 ion, presumed to be produced by the similar 
fragmentation pattern observed in the MS/MS spectrum of (–)-dictyostatin (Figure 4.3) was 16 
Da higher than that from the parent molecule. This confirmed that the oxygenation occurred 
between C19 and C26. The loss of three H2O produced the ion at m/z 495. The two most 
informative ions were observed at m/z 265 and m/z 465, which correspond, respectively, to the 
elimination of formaldehyde from the ions at m/z 295 and m/z 495. This strongly suggests that 
the hydroxylation occurred at one of the terminal methyl groups between C19 and C26. As with 
M1, it is possible that M3 was the hydroxyl derivative on 22-methyl group of (–)-dictyostatin 
after double bond migration. Double bond migration also generates another terminal methyl 
group on C25, a possibility that can not be excluded. The ion at m/z 393, produced by the 
cleavage of C1-O and C19-C20, was not detected in the MS/MS spectrum of M3. Instead, an ion 
at m/z 391 was observed. This ion can be explained by the cleavage of C21-O and C19-C20 and 
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elimination of H2O. The reason why the fragmentation took place between C21-O instead of C1-
O is possibly due to the influence of the migrated double bond. 
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Figure 4.9 MS2 spectrum of the protonated molecular ion (m/z 549) of metabolite M3. 
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Figure 4.10 Tandem mass spectrometry fragmentation pathways of the protonated molecular ion 
of M3. 
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     Metabolite M4. Metabolite M4 eluted after M3. The [M+H]+ ion of M4 was observed at m/z 
549, and the mass difference between M4 and the parent compound was 16 Da, indicating that 
M4 was a monooxygenation derivative. The fragmentation pattern of M4 was similar to that of 
M3 (see Figure 4.12). The MS/MS spectrum of M4 (Figure 4.11) exhibited two major fragment 
ions. One was at m/z 295, which corresponded to the cleavage of C12-C13 and C1-O. 
Subsequent elimination of H2O from the m/z 295 ion gave rise to the m/z 277, m/z 259, and m/z 
241 ions. The m/z 295 ion was 16 Da higher than the m/z 279 ion observed in the MS/MS 
spectrum of (–)-dictyostatin. This indicated that the oxygenation took place between C13-C26. 
The cleavage of C9-C10 and C12-C13 followed by the loss of water produced the ion at m/z 
413.The same fragmentation pattern of the parent compound generated the ion at m/z 415. In 
addition, an intense signal was observed at m/z 469, 16 Da higher than the m/z 453 ion, produced 
by the cleavage C21-C22 as mentioned before, observed in the MS/MS spectrum of the parent 
compound. This difference indicated that the hydroxylation did not occur between C21 and C26. 
Therefore, the position of hydroxylation was between C13 and C20.  It is highly possible that the 
hydroxylation took place on C20, which is more electrophilic than C13-C19. Therefore, M4 is 
proposed to be the 20-hydroxyl derivative of (–)-dictyostatin. The ion detected at m/z 359 
confirms the structure. It corresponds to the cleavage of C1-O, C21-C22 and C6-C7. Subsequent 
elimination of CO gave rise to the ion of m/z 331. The typical fragment ion at m/z 393 was not 
observed in the MS/MS spectrum of M4. Instead, an ion at m/z 391 was detected. It can be 
explained by the cleavage of C21-O and C19-C20 and loss of H2O. The reason why the ion was 
cleaved in C21-O but not in C1-O may be the same as for M3. Hydroxylation C20 would 
influence the cleavage of C21 and C19. 
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Figure 4.11 MS2 spectrum of the protonated molecular ion (m/z 549) of metabolite M4. 
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Figure 4.12 Tandem mass spectrometry fragmentation pathways of the protonated molecular ion 
of M4. 
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    Metabolite M5. M5 eluted after M4 but before the parent compound. The [M+H]+ ion of M5 
was observed at m/z 549, 16 Da higher than that of parent compound, suggesting M5 to be a 
monooxgenation product of (–)-dictyostatin. Major fragment ions were detected at m/z 295, m/z 
393, m/z 451, m/z 359 and m/z 309 (Figure 4.13). The ion at m/z 393 was produced by the 
cleavage of C1-O and C19-C20, also observed in the MS/MS spectrum of parent compound, 
indicating that the hydroxylation took place between C20-C26. Further loss of H2O from m/z 393 
gave the fragment ion at m/z 375. The appearance of the ion at m/z 295 supported the conclusion 
that the metabolism occurred between C20-C26. The ion at m/z 295 was generated by the 
cleavage of C12-C13 and C1-O, and the loss of a water molecule. The cleavage of C21-C22 and 
further loss of a water molecule gave rise to another important diagnostic ion at m/z 451. This 
observation suggested that the hydroxylation did not take place on between C21-C26, but rather 
on C21 itself or its methyl substituent. Hydroxylation of C21 has already been assigned to M4; 
therefore it is highly likely that M5 is hydoxylated on the terminal methyl group on C21. 
Subsequent loss of formaldehyde from the ion at m/z 295 gave rise to the most informative ion, 
at m/z 265, which strongly supports the structural assignment given to M5. The ion at m/z 359 
was observed in MS/MS spectrum of M5, corresponding to the cleavage of C1-O, C21-C22 and 
C6-C7. The cleavage of C20-C21 and C6-C7 gave rise to the fragment ion at m/z 309. All these 
fragment ions were consistent with the assigned structure of M5 (see proposed fragmentation 
pathways in Figure 4.14). 
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Figure 4.13 MS2 spectrum of the protonated molecular ion (m/z 549) of metabolite M5. 
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Figure 4.14 Tandem mass spectrometry fragmentation pathways of the protonated molecular ion 
of M5. 
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             Metabolite M6. M6 was the only metabolite to elute after the parent compound. This 
indicated a lower polarity of M6 compared to the parent compound. M6 gave an [M+H]+ ion at 
m/z 549, 16 Da higher than the parent compound, suggesting M6 to be a monooxygenation 
product. The lower polarity than the parent compound suggested that this was not a simple 
hydoxylation product. The MS/MS spectrum of M6 showed a product ion at m/z 279 (Figure 
4.15), which corresponded to the cleavage of the C12-C13 and C1-O bonds and elimination of a 
water molecule. This implied that the oxidation did not take place between C13 and C26. The 
cleavage of the C1-O and C19-C20 bonds gave rise to the typical fragment ion at m/z 409, 16 Da 
units higher than that of parent compound. Further elimination of water from m/z 409 gave rise 
to the m/z 391 ion, suggesting that the oxidation occurred on a carbon between C1 and C12. The 
cleavage of the C21-C22 bond produced the ion at m/z 469. The most important diagnostic ion in 
the MS/MS spectrum of M6 was the high intensity ion observed at m/z 309. Further elimination 
of water from m/z 309 gave rise to the ion at m/z 291. This unusual ion at m/z 309 was 
structurally significant. Its existence implied the oxidation took place on a carbon between C6 
and C12. It is therefore highly possible that M6 was generated by the epoxidation of the C10-
C11 double bond followed by intramolecular attack by the C7-hydroxyl group to give a 
tetrahydrofuran derivative (see proposed biotransformation pathways of dictyostatin in Figure 
4.17). The high intensity of the ion at m/z 309 can be explained by the stable furan ring formed 
after the cleavage of the C6-C7 and C20-C21 bonds followed by the loss of water molecules 
(Figure 4.16). 
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Figure 4.15 MS2 spectrum of the protonated molecular ion (m/z 549) of metabolite M6. 
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Figure 4.16 Tandem mass spectrometry fragmentation pathways of the protonated molecular ion 
of M6. 
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Figure 4.17 Metabolic pathways of (–)-dictyostatin catalyzed by pooled human liver 
microsomes. 
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4.4 DISCUSSION 
The results presented here show that pooled human liver microsomes convert (–)-
dictyostatin into at least six metabolites. The proposed biotransformation scheme is summarized 
in Figure 4.17. The structures of the identified metabolites indicate that macrolactone ring 
opening, which appears to proceed via hydrolysis of the lactone ester bond, is one of the main 
metabolic routes for (–)-dictyostatin. This was indeed due to microsomal enzymes, as ring 
opening did not occur when the microsomes were not in an activated state. Another main 
metabolic route is the oxygenation of the C20-C26 subunit. The epoxidation of the C10-C11 
double bond following the attack of oxygen atom on C7 also leads to the unusual metabolite M6. 
Oxygenation on C20-C26. Most of the metabolites of (–)-dictyostatin were identified to 
have a hydroxyl group on C20-C26, with or without lactone ring opening, by MS/MS 
experiments using 3D ion trap mass spectrometer. These oxidation products of C20-C26 were 
also the most abundant human liver microsomal metabolites of (–)-dictyostatin. Among these, 
hydroxylation of the terminal methyl group on C22 was an interesting pathway. The 
hydroxylation of the terminal methyl group on C22 formed the metabolite M1. The hydrolysis of 
the lactone ring of M3 led to the formation of metabolite M1. These two metabolites also showed 
evidence of double bond migration. These products were formed most likely due to the 
delocalization of the unpaired electron from C22 to the terminal methyl group of C22. This 
electron delocalization generated a radical on the terminal methyl group either on C22 or on C25. 
The unpaired electron on the terminal methyl group would be expected to be more stable than the 
unpaired electron on C22, and the steric hindrance for oxygen rebound from cytochrome P450 is 
much lower than that of C22. Therefore, the radical formed by double bond migration gave the 
most favorable electronic and steric considerations for the site of attack. This is a common type 
 113 
of transformation observed in other allylic systems (Fischer IU, et al., 1990). Another interesting 
observation was the formation of metabolites M4 and M5. Metabolite M4 was the hydroxylation 
product on C20 formed through the classical hydrogen abstraction/oxygen-rebound mechanism. 
The two oxygen atoms on C21 and C19 provide an electron withdrawing influence on C20, 
making the hydrogen atom on C20 acidic and relatively easier to be abstracted by CYP enzymes. 
The following oxygen rebound onto C20 gave rise to the metabolite M4. However, the unpaired 
electron on C20 was likely not stable because of the two electron withdrawing groups on C19 
and C21, and this unpaired electron was likely delocalized onto the terminal methyl group on 
C20. The radical structure formed by this delocalization was the favorable structure in terms of 
electronic and steric considerations. The following oxygen rebound generated the metabolite M5.  
To help explain these results, the physical-chemical properties of (–)-dictyostatin and its 
metabolites were calculated by Cerius2 (Accelrys, Inc). A summary of these parameters are 
shown in Table 4.2.  
 
Table 4.2 Calculated parameters of (–)-dictyostatin and its metabolites 
 ALogP98 Dipole-mag H bond accep H bond donor 
(–)-dictyostatin 5.36 4.413 6 4 
M1 3.87 10.146 8 7 
M2 3.81 8.364 8 7 
M3 4.48 6.003 7 5 
M4 4.55 4.986 7 5 
M5 4.37 3.027 7 5 
M6 4.51 5.562 7 4 
 
 
The calculated logP values for M1 and M2 suggested that these two metabolites have 
higher aqueous partitioning than the parent compound and other metabolites. Although the logP 
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values of M1 and M2 were close to each other, the dipole moment of M1 was higher than that of 
M2. Therefore, M1 eluted from the C18 column earlier than M2. The logP value of M3 was 
lower than that of M4, and the dipole moment of M3 was higher than that of M4, so there is no 
surprise that the retention time of M4 was longer than that of M3. The logP value of M5 was 
lower than those of M3 and M4; however, the dipole moment of M5 was much lower than those 
of M3 and M4. Meanwhile, the hydroxyl group on the terminal methyl group of C20 might form 
an intramolecular hydrogen bond with the oxygen atom on carbonyl group and decrease the H 
bond acceptor and donor properties of M5. Based on these considerations, the retention of M5 
was later than those of M3 and M4. 
 Formation of the metabolite M6. Another type of metabolic reaction seen with (–)-
dictyostatin was expoxidation of the double bond on C10-C11. This metabolic pathway was 
found to be the major route for the structurally related microtubule stabilizer (+)-discodermolide 
(Chapter 3). Although no intact epoxide metabolite was observed in the incubation mixture with 
human liver microsomes, the cyclization derivative of (–)-dictyostatin was envisioned to be 
formed by the attack on the epoxide moiety by the neighboring hydroxyl group on C7. Attack of 
this hydroxyl oxygen, depending upon which of the two carbons atoms in the oxirane ring is 
attacked, could lead to either a five- or a six-membered ring. However, only the relatively more 
stable five-membered ring system was observed. The epoxide intermediate could pose a toxicity 
risk as oxiranes are a potential target of endogenous nucleophiles. Although the calculated logP 
value and dipole moment of M6 was not too low, the later retention time of M6 might be 
explained by the formation of multiple intra-molecular hydrogen bonds amongst the hydroxyl 
groups on C9, C11 and C13. These multiple intra-molecular hydrogen bonds dramatically 
decrease the number of potential H bond-acceptor and -donor sites in M6.  
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Biotransformation pathways of (–)-dictyostatin and (+)-discodermolide. Based on 
their several structural similarities, (+)-discodermolide and (–)-dictyostatin likely interact with 
tubulin in the same or very similar ways. Previous studies show that the conformation of 
discodermolide as determined from NMR data when the molecule is incubated with tubulin is 
closely related to the solution structure of dictyostatin in water (Sanchez-Pedregal VM, et al., 
2006). This result strongly implies that the interaction of these two compounds with CYP 
enzymes might also have common features. Not surprisingly, oxygenation products near the 
terminal diene group of discodermolide and the side chain diene group of dictyostatin were 
detected in these two compounds, and double bond migration took place on the diene groups of 
both of these compounds. Saturation of the diene group may increase the metabolic stability of 
dictyostatin, and a structure proposed for future synthesis is shown in Figure 4.18. 
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Figure 4.18 Proposed structure of an analogue of dictyostatin to be synthesized. 
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5.0  METABOLIC STABILITY STUDIES OF (+)-DISCODERMOLIDE AND (-)-
DICTYOSTATIN 
5.1 INTRODUCTION 
Historically, drugs have been discovered with much assistance from serendipity and luck. 
Recent advances in chemistry, molecular biology and computational chemistry have provided the 
means for rapid attainment of chemical diversity and both virtual and real high-throughput 
screening against biological targets (Burkhard P, 1999; Shuker SB, 1996; Kiyama R, 1999; 
Broach JR, 1996; Fernandes PB, 1998; Silverman L, 1998). Although high-throughput screening 
has substantially accelerated the drug discovery process, more than 40% of drug candidates fail 
during clinical trials because of unfavorable drug metabolism and pharmacokinetic properties 
(Brennan MB, 2000; Prentis RA, 1988; Cunningham MJ, 2000). Hence, evaluation of  metabolic 
and pharmacokinetic properties in the drug discovery stage has been recognized as an important 
tool to enhance the success rates in clinic trial. In the present study, a metabolic stability 
screening approach (Obach RS, 1997) was used to determine the in vitro half-lives of the 
microtubule stabilizers (+)-discodermolide and (–)-dictyostatin. These half-life values were also 
converted to the in vitro CLint’ using a published forumula (Obach RS, 1999). 
Discodermolide and dictyostatin are potent microtubule stabilizing agents from marine 
sponges. Both are promising candidates to be anticancer drugs. However, the pharmacokinetic 
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profile of discodermolide is less than desirable, and the studies described in Chapters 3 and 4 
show that these two compounds are extensively metabolized by human liver microsomes. One of 
the objectives in this study was to determine the extent of metabolic biotransformation of these 
two compounds by hepatic metabolism enzymes.  Therefore, one can decide whether it is worth 
modifying the chemical structures of these two compounds to improve their metabolism and 
pharmacokinetic properties. 
 
5.2 MATERIALS AND METHODS 
Chemicals. The compounds used as internal standards, NC2-165 [(1S,2S,3R,8S,9R,10S)-
3,9-dihydroxy-14-(4S-hydroxy-3R,5R-dimethyl-6-oxotetrahydropyran-2S-yl)-1-isopropyl-2,8,10-
trimethyltetradeca-6Z,11Z-dienyl carbamate] and WHJ-360 
[(7R,8S,10R,13S,14R,15S,20R,21S,22S)-8,10,14,20-tetrahydroxy-7,13,15,21-tetramethyl-22-(1S-
methylpenta-2Z,4-dienyl)oxacyclodocosa-3Z,5E,11Z,16Z-tetraen-2-one], prepared and reported 
elsewhere (Choy N, 2003; Jung, W-H, 2007), were obtained from Prof. Dennis Curran. 
 
Microsomal Incubations. Pooled human liver microsomal incubations were repeated 
three times for each data point. Incubation mixtures (0.5 mL) contained 0.5 mg/mL of 
microsomal protein, 1 µM discodermolide or dictyostatin, and 100 mM phosphate buffer pH 7.4. 
The reaction was initiated by adding an NADPH regeneration system (BD Bioscience, San Jose, 
CA) that included 1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 0.4 U/mL glucose-6-
phosphate dehydrogenase, and 3.3 mM magnesium chloride. The incubation was carried out at 
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37 ºC. Aliquots (50 µL) were removed at different time points (0, 2, 4, 8 and 10 min) and the 
reaction was stopped in each aliquot by addition of 50 µL of cold methanol containing the 
respective internal standard (for discodermolide, the internal standard was 0.5 µM NC2-165; for 
dictyostatin, the internal standard was 0.05 µM WHJ360). Precipitated proteins were pelleted by 
centrifugation and the supernatant was used for analysis. Controls were the incubation without 
microsomal protein or without NADPH.  
 
LC-MS/MS analysis. The LC-MS/MS experiments were performed on a Thermo 
Finnigan TSQ Quantum Ultra triple quadrupole system. The spray voltage used was 3.8 kV and 
the scan mode was positive selective reaction monitoring (SRM) mode. The parameters of the 
mass spectrometer were optimized for each compound (Table 5.1). Separation was performed on 
a C18 YMC ODS-AQ (2.0 mm × 150 mm) column. The flow rate was 200 µL/min and the 
injection volume was 10 µL. Mobile phase A was water containing 0.1% formic acid, and 
mobile phase B was acetonitrile containing 0.1% formic acid. The gradients used for 
discodermolide and dictyostatin are given in Table 5.2. The retention times observed for 
discodermolide and its internal standard, NC2-165, were 4.19 min and 4.64 min, respectively. 
The retention times observed for dictyostatin and its internal standard, WHJ360, were 5.77 min 
and 5.71 min, respectively.  
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Table 5.1 Mass spectrometry conditions for discodermolide and dictyostatin in this analysis. 
 Capillary Temperature MS/MS (m/z) Collision Energy 
Discodermolide 300°C 594.000→334.074 15V 
NC2-165 300°C 512.000→415.256 15V 
Dictyostatin 320°C 533.000→497.173 16V 
WHJ360 320°C 517.000→481.251 16V 
 
Table 5.2 HPLC gradients for for discodermolide and dictyostatin in this analysis. 
 Discodermolide Dictyostatin 
Gradient A B A B 
0 min 85% 15% 80% 20% 
4 min 10% 90% 10% 90% 
6 min 10% 90% 10% 90% 
6.1 min 85% 15% 80% 20% 
11 min 85% 15% 80% 20% 
A: 0.1% formic acid/H2O  
B: 0.1% formic acid/ACN 
Retention times: Discodermolide, 4.19 min; NC2-165, 4.64 min 
                          Dictyostatin, 5.77 min; WHJ360, 5.71 min 
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5.3 RESULTS 
LC-MS/MS analysis using a triple quadrupole mass analyzer system is a powerful, and 
the most widely accepted, instrumental arrangement to perform mass spectrometric quantitative 
analyses. The high sensitivity and selectivity of such instruments allows for the quantitation of 
compounds present at low concentration in biological matrices. In the present case, the highest 
concentration of the compounds was 1 µM in a human liver microsomal reaction mixture. For 
this metabolic stability study, the triple quadrupole system was considered to be the best 
available tool. 
For quantitative purposes, the analogues of discodermolide and dictyostatin, NC2-165 
and WHJ360, were respectively used as the internal standards for these two drugs because of 
their respective similarities to the compounds of interest. The chemical structures of 
discodermolide and its internal standard, NC2-16, are shown in Figure 5.1, and the chemical 
structures of dictyostatin and WHJ-360 are shown in Figure 5.2. Figures 5.3 and 5.4 show these 
similarities in that the retention times of discodermolide and NC2-165 as well as those of 
dictyostatin and WHJ360. 
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Figure 5.2 Chemical structures of dictyostatin and WHJ360. 
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RT: 0.00 - 10.00
 
Figure 5.3 HPLC chromatograms of discodermolide (DCD) and its internal standard NC2-165. 
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RT: 0.00 - 11.00
 
Figure 5.4 HPLC chromatograms of dictyostatin (DST) and its internal standard WHJ360. 
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The metabolic stability profiles for discodermolide and dictyostatin are shown in Figures 
5.5 and 5.7, respectively. The x-axis shows time of incubation and the y-axis the percentage of 
parent drug remaining compared with the analyte/internal standard peak area ratio at t = 0 
(assigning t = 0 as 100%). The k values for discodermolide and dictyostatin were determined by 
linear regression (Figures 5.6 and 5.8). The calculated k values for the two drugs are shown in 
Table 5.3.  
 
 
 
 
 
 
 
 
 126 
0.10
1.00
10.00
100.00
0 5 10 15 20
Time (min)
Pe
rc
en
ta
ge
 o
f r
em
ai
ni
ng
 (%
)
 
Figure 5.5 Metabolic stability profile for discodermolide (n = 3). 
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Figure 5.5 Determination of the slope (-k) of the linear regression from ln percentage remaining 
versus incubation time relationship for discodermolide. 
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Figure 5.7 Metabolic stability profile for dictyostatin (n = 3). 
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Figure 5.6 Determination of the slope (-k) of the linear regression from ln percentage remaining 
versus incubation time relationship for dictyostatin. 
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Table 5.3 Summary of parameters for metabolic stabilities of discodermolide and dictyostatin. 
 Discodermolide Dictyostatin 
K (min-1) 0.321 0.335 
T1/2 (min) 2.2 2.1 
CLint’ (ml/min/kg) 396 378 
 
These k values were converted to in vitro half lives t1/2 (Table 5.3). The t1/2 values were 
calculated using the slope value k as follows:  
t1/2 = –0.693/k 
The short half lives of discodermolide and dictyostatin indicated that their in vivo 
clearance might be high. The intrinsic clearance (CLint’) was calculated using the following 
formula (Obach RS, 1999): 
CLint’= (0.693/in vitro t1/2)*(mL of incubation/mg of microsomal protein)*(45 mg 
microsomes/g liver)*(20 g liver/kg body weight) 
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5.4 DISCUSSION 
The metabolic transformation of drugs represents one of the major pathways by which 
they are cleared from the body. Metabolic transformation usually includes two phases, Phase I 
and Phase II transformation. The purpose of metabolic transformation is to increase the polarity 
of xenobiotics, including drugs, and enhance their clearance from the body.  Oxidation, reduction 
and hydrolysis reactions belong to Phase I category of metabolic reactions. In the drug discovery 
stage, it is impossible to obtain metabolic transformation information from humans. Also and 
unfortunately, studies from laboratory animals do not always accurately reflect what happens in 
human beings, partially because of the differences in drug-metabolism enzymes. Hence, the use 
of in vitro drug metabolizing systems to predict in vivo pharmacokinetic behavior has become an 
increasingly accepted part of drug discovery (Houston JB, 1994; Houston JB, 1997). The 
enzymes that metabolize drugs are distributed amongst the different organs and tissues, such as 
liver, intestine, kidney, lung and brain. Since the human liver is the major organ of drug 
metabolism in man, human liver-derived systems are the primary models used for studying drug 
metabolism. These systems include recombinant forms of the enzymes found in the liver, 
primary human hepatocytes, immortalized human hepatic carcinoma cell lines, liver slices, and 
human liver microsomes. Among these systems, the liver microsomal system is the most 
commonly chosen due to its several conveniences, particularly long shelf life (in a –80 oC freezer 
or liquid nitrogen storage). Human liver microsomes can not only be used predict the metabolic 
stability of a compound in humans, but also the body clearance, if the prediction meets the 
following assumptions: 1) metabolic clearance is the major pathway of total body clearance and 
the liver is the major organ of clearance; 2) oxidative metabolic transformation is the major route 
compared to other metabolic pathways such as Phase II metabolism; and 3) the rates of 
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metabolism and enzyme activities in vitro reflect those found in vivo. Usually, intrinsic clearance 
is obtained using kinetic data in the forms derived from the Michaelis-Menten equations (i.e., 
Vm/Km). However, such enzyme kinetic data is not always available in the discovery stage, 
especially in early points of the process because metabolite standards are not generally available. 
One of the simplest methods to predict human clearance is the in vitro half-life method used here 
(Obach RS, 1997). The in vitro t1/2 approach is based on two assumptions, that: 1) the apparent 
Km is far above the concentration of substrates used; and 2) there is no substrate inhibition or 
mechanism-based inhibition.  
The objective of this work in this chapter was to establish the metabolic stability 
screening method to select compounds with relatively low clearance for further development in 
microtubule stabilizing drug discovery. The second objective, as described in previous chapters, 
was to find the metabolic soft spots on discodermolide and dictyostatin so that future analogues 
could be designed with improved pharmacokinetic properties. The results indicate that 
discodermolide and dictyostatin are compounds that should have high hepatic clearance, and 
show that the compounds are extensively metabolized by human liver microsomes. Modification 
of these two compounds by substitution of metabolically stable groups that do not negatively 
alter their biological activity may be a promising strategy to find potent anticancer drugs with the 
acceptable pharmacokinetic properties. 
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6.0  SUMMARY 
Drug metabolism is an interdisciplinary science that involves the diverse research areas 
of chemistry, biochemistry, toxicology and analytical chemistry. Recently, the recognition of 
metabolic liabilities of drugs has attracted attention, moving the field closer to the starting points 
in drug discovery and development. In most cases, drug metabolism results in more hydrophilic 
metabolites without biological activity that are more easily cleared from body, and are regarded 
as detoxification pathways. Sometimes biotransformation of the parent drugs can, however, lead 
to the formation of reactive metabolites, which represent an underlying mechanism that gives 
rise to adverse drug reactions. Most of these bioactivation reactions can be attributed to 
cytochrome P450 enzymes, but, as seen in Chapter 1, some other oxidative enzymes such as 
myeloperoxidase can give rise to reactive metabolites.  
The possible mechanism(s) by which etoposide causes secondary leukemias have been 
studied for many years, yet the true answers to this mystery are still unclear. In this dissertation, 
a chemically reactive metabolite, etoposide ortho-quinone, was detected in HL60 cells. This 
reactive metabolite can react with the endogenous antioxidative barrier, glutathione, non-
enzymatically. The experiments demonstrated that the formation of the GSH adduct of etoposide 
ortho-quinone in HL60 cells was myeloperoxidase-dependent. The characterization of the GSH 
adduct of etoposide ortho-quinone in HL60 cells was performed using a 3D ion trap LC-MS 
instrument. This adduct was synthesized using normoisotopic materials. Comparison of the mass 
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spectra gave confidence regarding the structure of the adduct. The adduct was also synthesized in 
stable isotope-labeled form for use as an isotope dilution mass spectrometric internal 
standard.The ability to detect, characterize, and quantify the GSH adduct in intact HL60 cells 
was demonstrated with these tools. These studies and the stable isotope labeled adduct will be 
important for future investigations of the mechanism(s) of etoposide-associated secondary 
leukemias and for estimating the risk of treatment-related secondary leukemias. Future studies 
will likely focus on developing an understanding of the role of etoposide metabolites in the 
myeloid leukemogenic process that is frequently associated with the clinical use of this 
antineoplastic agent. In this study, H2O2 was added to HL60 cells, found to increase the rate and 
extend of the reaction of etoposide with MPO. An alternative way to increase the concentration 
of H2O2 in HL60 cells would be to use an inhibitor of catalase, such as 3-Aminotriazole. 
In the early stages of drug discovery and development, it is important to identify 
metabolic soft spots on lead compounds. Low metabolic stability is a warning sign to medicinal 
chemists that they should modify their chemical structures in order to reduce metabolic rate as 
early as possible. Discodermolide and dictyostatin are two potent microtubule stabilizing agents 
derived from marine sponges. Although they have tremendous biological potency in vitro, they 
are extensively metabolized by CYP enzymes, which is interpreted here as being of low 
metabolic stabilities. Eight metabolites of discodermolide were detected after incubation with 
pooled human liver microsomes. The diene group on discodermolide was identified as a 
metabolic soft spot. Substitution of the diene group with a saturated system could therefore 
possibly decrease the metabolic rate and improve the drug’s metabolic and pharmacokinetic 
properties. If potency is retained in such an analogue, the dose needed could therefore also 
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possibly be reduced and, hopefully, also any toxicities caused by discodermolide. Such 
analogues have already been reported.  
Previous studies have shown that a lactone ring-unsaturated analogue of discodermolide 
has more biological potency. In the present study, a related lactone ring metabolite of 
discodermolide was formed by pooled human liver microsomes. An unsaturated lactone ring 
analogue of discodermolide might be a promising agent, as it would be expected to have higher 
metabolic stability (and perhaps even efficacy).  
At least six metabolites of dictyostatin were formed in the in vitro microsomal system. 
The chemical structures of dictyostatin and discodermolide share many similarities. After the 
examinations done with discodermolide, it came as no surprise that the exocyclic diene group of 
dictyostatin was also found to be a metabolic soft spot. As with discodermolide, an analogue 
with a saturated version of these two double bonds may represent a promising way to increase 
metabolic stability.  
 Another goal of this work was to establish a metabolic stability assay in the lab. In order 
to identify the compounds with optimal drug-like properties, a medicinal chemist should 
consider not only biological activity and potency, but also metabolic properties. The 
biotransformation of drug molecules is one of key processes by which drugs are cleared from the 
body. The liver microsomal system used here is a common experimental tool for the in vitro 
study of metabolic stability because the system is easy to prepare and use. For such studies, 
however, the requisite analytical instrument is a triple quadrupole LC-MS/MS system. 
Fortunately, one became available for use near the end of these dissertation studies. The results 
showed that the metabolic rate of discodermolide and dictyostatin were high in vitro and the half 
lives of these two compounds were within 10 minutes. The result also indicated that chemical 
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structure modification to discodermolide and dictyostatin should be made in order to improve 
their metabolic and pharmacokinetic properties. 
As mentioned early on in this dissertation, nuclear magnetic resonance (NMR) is often a 
necessary method to be used to generate more detailed information, especially for 
stereochemistry. NMR studies were not performed here, however, due to the limited amount of 
compounds available and the avaibility of a high field NMR spectrometer. Future studies will 
almost certainly be focused on the elucidation of the stereochemistry of the metabolites of 
discodermolide and dictyostatin using high field NMR.  
The CYP enzymes responsible for the formation of the metabolites of discodermolide and 
dictyostatin were not determined in this study because neither metabolite standards nor 
isotopically labeled parent compounds were available. Future steps should be: 1) synthesis of the 
metabolites of discodermolide and dictyostatin; 2) preparation of stable isotope labeled forms of 
discodermolide and disctystatin for quantitative studies; and 3) determination, through inhibitor 
(antibodies and/or competitive inhibitors) studies, of the CYP enzyme(s) responsible for the 
metabolism. 
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APPENDIX A 
LIST OF ABBREVIATIONS & SPECIALIZED NOMENCLATURE 
MPO  Myeloperoxidase 
GSH  Glutathione 
Topo II Topoisomerase II 
HL60 cells Human Leukemia 60 cells 
SA  Succinylacetone 
MLL  Mixed lineage leukemia genes 
t-AML  Treatment-related acute myeloid  leukemias 
MALDI Matrix-assisted laser dissociation ionization 
Q-TOF Quadrupole-time of flight 
ESI  Electrospray ionization 
XIC  Extracted ion chromatogram 
NMR  Nuclear magnetic resonance spectroscopy 
IR  Infrared spectrscopy 
CYP450 Cytochrome P450 
FMO  Flavin-containing monoxygenase 
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MAOs  Monoamine oxidases 
UGT  UDP-glucuronosyltransferase 
P-gp  P-glycoprotein 
DCD  Discodermolide 
DST  Dictyostatin 
CL  Clearance 
CLint’  Intrinsic clearance  
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